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ABSTRACT 
 
The vaginal microbiota of healthy reproductive-age women is dominated by Lactobacillus 
spp., which protect against numerous uropathogens. This study aims to identify lactobacilli 
with antagonist activity toward Candida, Chlamydia, and HIV that mostly affect women’s 
health. 
From vaginas of healthy women, we isolated seventeen Lactobacillus strains, highly 
represented in the vaginal microbiota: L. crispatus (BC1-BC8), L. gasseri (BC9-BC14), 
and L. vaginalis (BC15-BC17). 
The broadest anti-Candida activity was observed for L. crispatus (BC1, BC4, BC5) and L. 
vaginalis BC15. Most of lactobacilli reduced Candida adhesion to HeLa cells by multiple 
mechanism including exclusion, competition, and displacement. Histone deacetylases 
inhibition was hypothesized to support the antifungal activity of Lactobacillus. 
Next, mainly L. crispatus strains inhibited Chlamydia by secreting metabolites in a 
concentration/pH dependent mode at short contact times. Lactate production, vaginal 
acidification, and glucose consumption seemed to be crucial for the anti-Chlamydia 
activity. The metabolic profiles of Lactobacillus-conditioned medium (CM) also correlated 
with the anti-Chlamydia/Candida activity. 
Finally, lactobacilli inhibited HIV-1 replication in human tissues ex vivo by multiple 
mechanisms: Acidification. The pH of Lactobacillus-CM was ≤ 4.6. Tissue culture 
acidification with HCl to this pH abrogated HIV-1 replication. However, Lactobacillus-
CM, diluted 5-fold (neutral pH), also suppressed HIV-1 infection, as opposed to HCl-
treated medium at the same pH, suggesting the existence of other anti-HIV factors. Lactate. 
Addition of lactate isomers D and L to tissue culture, at the average titers found in all 
Lactobacillus-CM, inhibited HIV-1 replication. Isomer L was produced in higher 
quantities and was mostly responsible for HIV-1 inhibition. Virucidal effect. Incubation of 
HIV-1 in Lactobacillus-CM suppressed virus infectivity. Lactobacilli cells adsorbed HIV-
1, decreasing the number of virions. 
This results support role of lactobacilli in protecting the female genital tract from 
uropathogens, and are prerequisites for the development of new probiotic agents as an 
effective strategy to enhance vaginal health. 
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RIASSUNTO 
 
Il microbiota vaginale delle donne sane in età riproduttiva è dominato da specie di Lactobacillus, 
che proteggono contro numerosi patogeni urogenitali. Il presente studio ha come scopo 
l’identificazione di ceppi di lattobacilli con attività antagonistica verso agenti patogeni che 
maggiormente incidono sulla salute delle donne, in particolare Candida, Chlamydia e HIV. Da 
tamponi vaginali di donne sane abbiamo isolato diciassette ceppi di Lactobacillus altamente 
rappresentate nel microbiota vaginale: L. crispatus (BC1-BC8), L. gasseri (BC9-BC14) e L. 
vaginalis (BC15-BC17).  
Lo spettro anti-Candida più ampio è stato osservato per L. crispatus (BC1, BC4, BC5) e L. 
vaginalis BC15. La maggior parte dei Lactobacillus si sono dimostrati efficaci nell'inibire 
l'adesione di C. albicans sulle cellule epiteliali attraverso meccanismi di esclusione, competizione 
e spiazzamento del patogeno. L'inibizione dell’enzima istone deacetilasi è stata anche ipotizzata 
come meccanismo alla base dell'attività antifungina osservata. 
Posteriormente, abbiamo osservato che la maggior parte dei ceppi di L. crispatus, inibiscono 
efficacemente anche l'infettività di C. trachomatis, principalmente attraverso i metaboliti secreti 
nei surnatanti dei lattobacilli in maniera concentrazione/pH dipendente e nei brevi periodi di 
contatto tra lattobacilli e patogeno. La produzione di lattato da parte dei lattobacilli e la conseguente 
acidificazione dell'ambiente vaginale sembrano essere cruciali per la loro attività anti-Chlamydia, 
insieme al consumo di glucosio. I profili metabolici dei surnatanti dei lattobacilli sono stati correlati 
con la loro attività anti-Chlamydia/Candida. 
Infine, abbiamo dimostrato che lattobacilli vaginali inibiscono la replicazione di HIV-1 in tessuti 
umani ex vivo: Riduzione del pH. L'acidificazione del terreno di coltura tissutale con HCl a valori 
di pH pari a quelli misurati nel surnatante delle culture di lattobacilli (≤ 4.6) si è dimostrato 
sufficiente per abrogare la replicazione di HIV-1. Tuttavia, il surnatante dei lattobacilli, diluito per 
neutralizzarne il pH, è risultato mantenere l’attività anti-HIV-1, a differenza del terreno di cultura 
tissutale acidificato con HCl allo stesso valore di pH. Ciò suggerisce l'esistenza di altri fattori 
responsabili dell'inibizione di HIV-1. Produzione di acido lattico. L'aggiunta degli isomeri 
dell'acido lattico, D e L, al terreno di coltura tissutale alla concentrazione corrispondente alla 
quantità rilasciata nei mezzi di coltura dei lattobacilli, è risultato nell'inibizione di HIV-1, in 
particolare si è sottolineato il ruolo dell'isomero L, che viene prodotto in quantità maggiori rispetto 
all'isomero D. Effetto virucida. L'incubazione di HIV-1 con il surnatante dei lactobacilli si è 
dimostrato inibire significativamente l'infettività del virus. In più i lattobacilli stessi sono in grado 
di assorbire le particelle di HIV-1 sulla loro superficie, diminuendo il numero di virioni liberi. 
I nostri risultati supportano l’idea di un ruolo attivo da parte dei lattobacilli nella protezione della 
mucosa genitale femminile contro patogeni urogenitali, e forniscono un razionale per lo sviluppo 
di nuovi agenti terapeutici basati sui probiotici come strategia efficace per migliorare la salute 
vaginale. 
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1. INTRODUCTION 
 
1.1 The mucosa of the female reproductive tract as physical barrier against pathogens 
 
The upper female reproductive tract, which consists of the cervix, uterus, and fallopian 
tubes, is characterized by the presence of type I mucosa, a simple columnar epithelium 
formed by a single layer of ciliated columnar cells connected by tight junctions, and is 
generally considered to be sterile [Heinonen et al., 1985]. The mucosal epithelium in this 
upper habitat should thus be extremely efficient in recognizing and subsequently 
responding to microorganisms, and at the same time avoiding chronic inflammation. 
Introduction of bacteria into these tissues is typically associated with identifiable disease 
(endometritis or pelvic inflammatory disease). However, the results of several culture-
based investigations, documenting recovery of organisms from the endometrium of healthy 
asymptomatic women, challenge the notion of sterility [Hemsell et al., 1989]. 
 
The lower female reproductive tract comprises the vaginal canal and the ectocervix. 
They are constituted by type II mucosa, characterized by multiple layers of non-
keratinized-stratified squamous epithelium [Quayle, 2002]. In contrast to the upper female 
genital tract, cells of the squamous epithelium are not connected with tight junctions. This 
permits the transport of small molecules between the cells within the epithelial space, 
including small viruses and toxic compounds from pathogens [Hickey et al., 2011]. The 
mucosa of the lower genital tract is a habitat where normally numerous endogenous 
microorganisms coexist in dynamic equilibrium with the host. 
 
The layer of epithelial cells of the female genital mucosa are not only a physical barrier 
against pathogens, they are also able to recognize conserved microbe-associated molecular 
patterns via the expression of pattern recognition receptors, such as toll-like receptors and 
NOD-like receptors, which mediate the secretion of cytokines, chemokines, and 
antimicrobial peptides [Schaefer et al., 2004]. 
The epithelial cells from type I and type II mucosa in the female genital tract are also 
covered by a layer of mucus, consisting of mucins, which are complex high molecular mass 
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O-glycoproteins [Andersch-Bjorkman et al., 2007]. The mucus in type I mucosa is 
produced by specialized goblet cells, similar to the ones in the gastrointestinal tract, while 
the mucus in type II mucosa is produced by local mucus-secreting epithelial cells 
[Andersch-Bjorkman et al., 2007]. An important characteristic of the cervico-vaginal 
mucus is the low pH, between 4 and 5, that protect the host from pathogenic bacteria, yeast, 
and viruses. 
 
1.2 Vaginal microbiota 
 
The mucosa of lower female reproductive tract is an ecological habitat where several 
aerobe and anaerobe microorganisms coexist in a dynamic equilibrium; these communities 
of microorganisms are denominated as “vaginal microbiota”. The vaginal microbiota plays 
an important role in women’s health, influencing their development, physiology, 
immunity, and nutrition. It constitutes the first line of defense for the host by excluding 
invasive nonindigenous organisms that may cause disease [Chen et al., 2015; Hickey et al., 
2012]. The homeostasis of the vaginal communities results from complex interactions and 
synergies between the host and different microorganisms that colonize the vaginal mucosa 
(Figure 1) [Larsen and Monif, 2001; Sobel, 1997]. 
 
 
Figure 1. Homeostasis of vaginal communities 
Chapter 1: Introduction 
	 3	
1.2.1 Composition of the vaginal microbiota 
 
Numerous studies have been done to characterize the vaginal microbial communities of 
healthy, asymptomatic, reproductive age women. Although these studies were based on 
various analytical methodologies sampling different regions of the female genital tract, 
women from different ethnic groups and geographical area, all consistently demonstrated 
that the vaginal microbiota composition may vary within and among women. Factors 
influencing the normal vaginal microbiota may include age, hormone levels, menstrual 
cycle stage, pregnancy, genetic background, exposure to sexually transmitted agents, 
immune status, use of antibiotics, sexual intercourse, vaginal lubricants, douching, and 
possibly diet and nutritional status [Eschenbach et al., 2000; Larsen and Galask, 1982; 
Smith et al., 1982; Vasquez et al., 2002]. 
Despite marked differences in the species composition of the vaginal microbiota among 
women, it appears that all are probably dominated by homofermentative lactic acid 
bacteria. This suggests that in reproductive age women, despite differences in the vaginal 
microbiota, the ecological function of various bacterial communities in creating a low pH 
environment through the production of organic acids is conserved [Ravel et al., 2011; Zhou 
et al., 2007; Zhou et al., 2010]. 
 
The most detailed study published so far used deep sequencing of bacterial 16S ribosomal 
RNA PCR products to probe the vaginal microbiota in 396 women of childbearing age 
from different ethnic groups (white, black, hispanic, and asian in North America) [Ravel 
et al., 2011]. In this study, the microbial communities of reproductive-aged women were 
clustered into five groups (Figure 2): community groups I, II, III, and V were dominated 
by Lactobacillus species, L. crispatus, L. gasseri, L. iners, and L. jensenii, respectively, 
while community group IV contained a diverse assemblage of facultative and strictly 
anaerobic bacteria, sometimes associated with vaginal symptoms, including Gardnerella 
vaginalis, Atopobium vaginae, Mobiluncus spp., Prevotella spp. and other taxa in the order 
Clostridiales; this latter group was over represented in black and hispanic women [Ravel 
et al., 2011]. Comparable results were obtained in a study of healthy, reproductive age 
Caucasian, black, and Japanese women [Zhou et al., 2007; Zhou et al., 2010]. The findings 
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of these studies indicate there is a limited number of different kinds of vaginal microbial 
communities in asymptomatic, apparently healthy women. Moreover, from studies of 90 
menarcheal adolescent women (13–18 years), it appears that these bacterial communities 
are established in puberty and may reside in women until menopause [Yamamoto et al., 
2009]. 
An important finding from these studies is that the distribution of bacterial community 
types varies significantly among women from different ethnic backgrounds. 
 
 
Figure 2. Representation of vaginal bacterial community groups within 4 ethnic groups of 
women. The number of women from each ethnic group is in parentheses. The roman 
numerals indicate the 5 common vaginal bacterial community groups [Ravel et al., 2011]. 
 
In addition, diversity in the vaginal microbiota in different geographic area was also 
observed. For example, the vaginal microbiota of Nigerian, Belgian, and Brazilian women 
appear to be dominated mainly by L. iners [Anukam et al., 2006; Martinez et al., 2008; 
Vitali et al., 2007], whereas in Swedish, German, and Turkish women, L. crispatus was the 
most dominant species [Kilic et al., 2001; Thies et al., 2007; Vasquez et al., 2002]. 
Furthermore, the vaginal microbiota of Indian and Bulgarian women is dominated by L. 
reuteri, L. gasseri, and L. fermentum [Dimitonova et al., 2008; Garg et al., 2009]. 
 
Most of the studies to characterize the vaginal microbiota have employed cross sectional 
designs at a single time point. However, a longitudinal study to characterize daily 
fluctuations in the composition of the vaginal microbiota has been also reported by Gajer 
and colleagues [Gajer et al., 2012]; they analyzed the temporal dynamics of the 
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composition of vaginal bacterial communities in 32 reproductive age women over a 16-
week period. The study showed that some bacterial communities change markedly over 
short time periods transitioning between groups and most frequently to the group IV, 
whereas others are relatively stable. In some cases, group transitions were triggered by 
menstruation or sexual behaviors, but in other cases they seem to be driven by 
uncharacterized factors [Gajer et al., 2012]. Similar results were reported in normal and 
disturbed vaginal microbiota [Brotman et al., 2008; Brotman et al., 2010; Ravel et al., 2013; 
Srinivasan et al., 2008]. These longitudinal studies highlight the highly dynamic nature of 
vaginal microbial communities and emphasize the need to better understand the underlying 
biological factors modulating fluctuations in composition and functions that affect host 
physiology. 
 
1.2.2 Changes of vaginal microbiota during a women’s lifespan 
 
The vaginal microbial communities experiences significant structural changes at various 
stages in a women’s life and are directly linked to the level of estrogen in the body [Farage 
and Maibach, 2006]. Major changes in the vaginal physiology and microbiota over a 
women's lifetime are largely influenced by transitional periods such as puberty, menopause 
and pregnancy, while daily fluctuations in microbial composition are more likely to be the 
results of daily life activities and behaviors [Smith and Ravel, 2017]. 
The initial bacterial colonization occurs at birth, when the newborn is first exposed to her 
mother’s vaginal tract if delivered vaginally, or by the skin bacteria in the case of a 
caesarian-section delivery [Dominguez-Bello et al., 2010]. Nevertheless, the majority of 
the vaginal bacteria originate from the gastro intestinal microbiota through a natural 
ascension independent of hygienic practices or from the surrounding skin epithelium 
[Dominguez-Bello et al., 2010]. During perinatal development, residual maternal estrogen 
induces thickening of the vaginal epithelium and the deposition of glycogen in the 
epithelial cells. Through the exfoliation of epithelial cells, glycogen is released, thereby 
favoring the colonization of glucose-fermenting microorganisms resulting in a lowering of 
the vaginal pH. However, this effect is transitory, since the subsequent metabolism of 
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maternal estrogen is accompanied by thinning of the vaginal mucosa, a reduction of the 
level of glycogen, and a concomitant increase in vaginal pH [Farage and Maibach, 2006]. 
In prepuberal girls, the pH of the vagina is nearly neutral, and cultivation-dependent 
methods have shown vaginal colonization by diverse assemblages of aerobic, strictly 
anaerobic, and enteric species of bacteria (Figure 3) [Alvarez-Olmos et al., 2004; 
Hammerschlag et al., 1978]. 
Between the ages of 8 and 13 years, the production of estrogen increases and consequently 
the thickness of the vaginal epithelium and the production of glycogen are incremented as 
well [Farage and Maibach, 2006]. Glycogen is directly or indirectly nutritionally necessary 
for the maintenance of Lactobacillus spp. [Brotman et al., 2010; Galhardo et al., 2006]. 
These new environmental conditions permit the colonization of microorganisms capable 
of fermenting glycogen to lactic acid and the concomitant acidification of the vaginal 
environment that is characteristic of reproductive age women (Figure 3) [Farage and 
Maibach, 2006; Hammerschlag et al., 1978]. Interestingly, Lactobacillus spp. was 
originally thought to directly ferment glycogen in the vagina. However, recent evidence 
suggests that human α-amylase catabolizes glycogen into smaller polymers, namely 
maltose and maltotriose, which can then be used by Lactobacillus spp. for metabolism, 
even in newborns who have residual circulating maternal estrogen [Spear et al., 2014]. 
During the menopause, estrogen levels again decrease, and this is accompanied by atrophy 
of the vaginal epithelium and reduced cervico-vaginal secretions [Farage and Maibach, 
2006]. In postmenopausal women, the levels of estrogen once again decline, reducing the 
deposition of glycogen thereby selecting for a high diversity of bacterial species (Figure 3) 
[Larsen and Galask, 1982].	
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Figure 3. Vaginal microbiota during women’s life [Petrova et al., 2013]. 
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1.3 Vaginal Lactobacillus spp. 
 
Healthy vaginal microbiota is generally dominated by the Gram-positive bacteria, 
Lactobacillus spp. [Hyman et al., 2005; Ravel et al., 2011]. Lactobacilli form a critical line 
of defence maintaining the normal vaginal microbiota by preventing overgrowth of 
pathogenic and opportunistic organisms [Macklaim et al., 2011; O'Hanlon et al., 2013; 
Ronnqvist et al., 2006]. 
 
In general, the presence of high numbers of lactic acid producing bacteria in the vagina is 
often associated with “healthy” and low numbers or absence as being “abnormal”. The 
members of the genus Lactobacillus are considered as a keystone species because of their 
well-known ability to produce lactic acid through the fermentation of sugars. Albert 
Döderlein reported for the first time their existence by culturing these bacteria from vaginal 
secretions. He found that they produced lactic acid, which in turn inhibited growth of 
pathogens both in vitro and in vivo [Döderlein, 1892]. “Döderlein’s bacillus” was later 
classified in 1928 as Lactobacillus acidophilus [Thomas, 1928]. Subsequent advances in 
culture techniques and in biochemical characterization of microorganisms have led to 
important additional insights. In the 1980s, it was determined that L. acidophilus was not 
a single species, but rather a group of closely related, obligatory homofermentative species 
collectively known as the L. acidophilus complex [Lauer et al., 1980]. 
As a result, the group was divided into DNA-homologous groups, to form many separate 
species, which are L. acidophilus, L. amylolyticus, L. amylovorus, L. crispatus, L. 
gallinarium, L. gasseri, L. iners, L. jensenii, and L. johnsonii [Du Plessis and Dicks, 1995]. 
However, the culture-dependent methods did not permit to identify several Lactobacillus 
species in the vagina. For example, most culture-dependent methods fail to identify L. 
iners, that was only first described in 1999 because it is not able to grow in the media 
typically used to isolate Lactobacillus [Falsen et al., 1999]. 
 
Major advances in DNA sequencing technology over the last decade have fundamentally 
changed the way to assess microbial community structure and composition. For 
investigations of bacterial diversity, these methods commonly utilize 16S rRNA gene 
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sequences to compare and classify taxa. This approach investigates DNA sequences 
extracted directly from samples. Typically, partial 16S rRNA gene sequences are amplified 
using primers that anneal to highly conserved sequences, and the resulting amplicons are 
sequenced. Phylogenetic analyses of the sequences allow the classification of phylotypes 
and determination of the numerically dominant taxa in a community. Other methods that 
rely on other conserved genes (cpn60, rpoC, uvrB, or recA) have also been developed but 
are not as widely used [Schellenberg et al., 2009; Van der Lelic et al., 2006]. 
 
1.3.1 Lactobacillus-associated protective mechanisms 
 
Dominant vaginal Lactobacillus species exert important health-promoting effects to 
maintain the homeostasis of the host and their dominance in the vaginal habitat. This is 
accomplished by various direct and/or indirect mechanisms such as: the reduction of the 
vaginal pH by producing organic acids, especially lactic acid; the production of 
antimicrobial substances (bacteriocins, hydrogen peroxide, etc); the competition with other 
microorganisms for the nutrients and for adherence to the vaginal epithelium; maintenance 
of the vaginal epithelium integrity by stimulating mucus secretion and modulating the 
immune response. These principal mechanisms are described below. 
 
1.3.1.1 Lactic acid 
 
Lactic acid is the principal metabolite produced by vaginal microbiota, thanks to its ability 
to metabolize glycogen-derived products under anaerobic conditions. 
Numerous studies reported that lactic acid is able to maintain healthy host physiological 
functions since it has been shown to directly inhibit the vaginal colonization of numerous 
pathogenic microorganisms such as Chlamydia trachomatis [Gong et al., 2014; Nardini et 
al., 2016] and potentially both HSV-2 and HIV in vitro, ex vivo, and in vivo if there is 
sufficient lactic acid to acidify the vagina to pH < 4 [Aldunate et al., 2013; Conti et al., 
2009; Nahui Palomino et al., 2017]. Lactic acid also inhibits a broad range of bacterial 
vaginosis-associated microbes at pH < 4.5 [O'Hanlon et al., 2011, 2013]. Other studies 
showed that lactic acid can stimulate host immune responses, for example by inhibiting the 
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pro-inflammatory mediators IL-6, IL-8 and IL-1RA; by inducing a Th17 response via IL-
23; and by facilitating the release of mediators from vaginal epithelial cells and stimulating 
antiviral response by the release of antimicrobial effector molecules from epithelial cells 
[Hearps et al., 2017; Mossop et al., 2011; Witkin et al., 2011]. 
 
1.3.1.1.1 d- l-Lactic acid isomers 
 
Lactic acid isomers may also play a role in determining host response and the subsequent 
host microbiota relationship. Lactic acid exists in the vagina in both “d” and “l” isomers; 
lactic acid is also produced by vaginal epithelial cells under the control of estrogen only. 
However, vaginal microbiota, and not host epithelial cells, contributes to the production of 
most of the lactic acid present in the vagina [Boskey et al., 2001; Boskey et al., 1999]. 
Lactobacilli can produce both the d- and l-chiral isomers of lactic acid, while humans 
produce only the l-isomer, except for a small quantity of the d-isomer released via the 
methylglyoxal pathway [Ewaschuk et al., 2005]. Of importance, among the four most 
common lactobacilli species in the human vagina L. iners does not produce d-lactic acid 
and is not able to produce the l-lactic acid in abundance, in contrast to L. crispatus and L. 
gasseri, while L. jensenii produces only d-lactic acid [Witkin et al., 2013], suggesting 
potential Lactobacillus species-specific effects on the host. 
Nevertheless, few studies reported on the role of lactic acid isomers. According to the study 
conducted by Witkin et al., d-lactic acid down-regulated the production of matrix 
metalloproteinase (MMP)-8. MMP-8 in the vagina alters cervical integrity favoring the 
entrance of bacteria to the upper genital tract. Therefore, a high d-lactic acid level, present 
when L. crispatus, L. jensenii and/or L. gasseri are abundant in the vagina, may lower the 
bacterial transport to the uterus protecting the woman from upper genital tract infections 
and infection-related preterm birth [Witkin et al., 2013]. Nunn et al. showed that HIV-1 
virions were generally trapped in cervico-vaginal mucus with relatively high 
concentrations of d-lactic acid from a L. crispatus-dominant microbiota. In contrast, HIV-
1 virions diffused rapidly through cervico-vaginal mucus with low concentrations of d-
lactic acid from L. iners-dominant microbiota or significant amounts of G. vaginalis, 
suggesting that the vaginal microbiota, including different species of Lactobacillus, can 
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alter the diffusional barrier properties of cervico-vaginal mucus against sexually 
transmitted viruses through the production of d-lactic acid [Nunn et al., 2015]. 
On the other hand, Aldunate and colleagues, observed that l-lactic acid, and not d-lactic 
acid, at physiological concentrations, exerted potent HIV virucidal activity [Aldunate et 
al., 2013]. Moreover, by analyzing vaginal fluids from women with vaginal disorders, 
Beghini et al., observed that women with bacterial vaginosis were found to be deficient in 
both isomers, while those with vulvovaginal candidiasis had elevated l-lactic acid [Beghini 
et al., 2015]. 
 
1.3.1.2 Hydrogen peroxide 
 
Another property of most vaginal lactobacilli is their ability to release hydrogen peroxide 
(H2O2) in appreciable amounts in vitro [Eschenbach et al., 1989]. The H2O2 of microbial 
origin and halide (Cl−, Br−, I−) or pseudohalide (SCN−) ions is oxidized by peroxidase 
forming the corresponding hypohalous acid or halogen, which exerts potent toxic 
properties against bacteria, fungi, viruses or mammalian cells [Klebanoff and Coombs, 
1991; Klebanoff et al., 1991]. 
It has been determined that 96–98% of cultivable vaginal Lactobacillus isolates from 
healthy women are H2O2-producers in vitro [Eschenbach et al., 1989; Rabe and Hillier, 
2003], suggesting that H2O2 could be an important bacterial metabolite for protection 
against pathogenic microorganisms. In fact, Wilks and colleagues reported that the 
presence of H2O2-producing Lactobacillus strains such as, L. jensenii, L. crispatus, and L. 
gasseri is associated with a reduced risk of bacterial vaginosis, preterm birth, and 
chorioamnionitis [Wilks et al., 2004]. The presence of H2O2-producing lactobacilli also 
correlates with a reduced risk of acquiring sexually transmitted pathogens, such as 
Neisseria gonorrhoeae, C. trachomatis, and HIV [Baeten et al., 2009; Saigh et al., 1978; 
Wiesenfeld et al., 2003]. Moreover, Fitzsimmons and Berry reported the inhibition of 
Candida albicans by H2O2-producing L. acidophilus [Fitzsimmons and Berry, 1994], 
although this result was not confirmed by other studies [Hawes et al., 1996; Sobel and 
Chaim, 1996]. 
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However, the H2O2-production by lactobacilli has not been measured in vivo; therefore, the 
biological relevance of H2O2 in the prevention of urogenital diseases remains still 
unknown. Martin and Suarez work showed that H2O2 is only produced by lactobacilli when 
cultures are agitated, indicating that H2O2 is produced only in the presence of oxygen. 
Furthermore, H2O2 was degraded when the bacteria were grown in the presence of iron-
containing compounds such as hemin or hemoglobin, and Fe3+ ions also induced 
degradation of H2O2 [Martin and Suarez, 2010]. These two findings, in addition to the fact 
that the vagina is microaerophilic and an iron-rich mucosal site, raises the question of 
whether lactobacilli can produce enough H2O2 amounts to inhibit pathogens in vivo [Martin 
and Suarez, 2010]. 
 
1.3.1.3 Adhesion to host cells 
 
Another postulated mechanism, by which lactobacilli would prevent pathogen colonization 
of vaginal epithelium, is through the adhesion to host cells. Lactobacilli bind to the surface 
of vaginal epithelial cells and compete for the adhesion sites with other microorganisms to 
prevent them from attaching and infecting host cells. Several vaginal Lactobacillus strains 
have been shown to block adhesion of pathogens to the vaginal epithelial cells in vitro, 
such as Escherichia coli, G. vaginalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Staphylococcus aureus, and Trichomonas vaginalis [Mastromarino et al., 2002; Osset et 
al., 2001; Phukan et al., 2013; Zarate and Nader-Macias, 2006]. Additionally, it was 
observed that lactobacilli have a higher affinity for the host cell receptors than pathogens, 
displacing even already host-adhered pathogens, such as G. vaginalis, N. gonorrhoeae and 
C. albicans [Boris et al., 1998; Mastromarino et al., 2002; Parolin et al., 2015; Spurbeck 
and Arvidson, 2008]. However, little is known about molecular mechanisms underlying 
host-bacteria physical interactions. Multiple components of the bacterial cell surface are 
likely to participate in this process, such as glycoproteins, carbohydrates, and lipoteichoic 
acid, as previously shown for Lactobacillus adherence to the vaginal epithelium [Boris et 
al., 1998; Chan et al., 1985]. 
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1.3.1.4 Coaggregation 
 
Lactobacilli could also protect the vaginal tract from infection by coaggregating with the 
pathogen, thereby sequestering the pathogen and preventing it from adhering to the host 
epithelium, thus facilitating its discharge by vaginal fluids and/or killing by antimicrobial 
metabolites secreted by lactobacilli [Mastromarino et al., 2002]. Coaggregation, as a 
mechanism of defense was first studied by Reid et al., observing for example that L. 
rhamnosus strongly coaggregated with E. coli strains, inhibiting their growth [Reid et al., 
1988]. Some vaginal lactobacilli, including L. gasseri, L. jensenii, and L. crispatus, can 
coaggregate with E. coli, although with different efficiency [Kmet and Lucchini, 1999]. 
This phenomenon is not restricted to E. coli, for instance L. salivarius, L. brevis, and L. 
gasseri can coaggregate with G. vaginalis and C. albicans [Mastromarino et al., 2002]. 
Although coaggregation can be an effective defensive mechanism adopted by some strains, 
it seems that is not utilized by all vaginal lactobacilli. 
 
1.3.1.5 Bacteriocins 
 
Bacteriocins are defined as small bactericidal proteins with a narrow spectrum of activity, 
inhibiting strains of the same or closely related species [Cotter et al., 2013]. These proteins 
appear to be capable to inhibit the colonization of pathogenic and opportunistic 
microorganisms and perhaps provide an advantage to maintain the wellness of the female 
genital tract. Strains of the most dominant vaginal Lactobacillus species in healthy women 
(L. gasseri, L. crispatus, and L. jensenii), as well as the most well characterized vaginal 
probiotic strain, L. rhamnosus GR-1, were found to produce bacteriocin-like compounds, 
these bacterocin-like compounds have been showed to exert microbicidal activity against 
G. vaginalis, C. albicans and E. coli [Kaewsrichan et al., 2006; McGroarty and Reid, 
1988]. On the other hand, some extensive studies of human vaginal lactobacilli isolates, 
such as, L. crispatus, L. jensenii, L. gasseri, L. vaginalis, and L. plantarum showed that 
none of these strains produced bacteriocins [Martin et al., 2008; Siroli et al., 2017]. Thus, 
bacteriocins may not be universally produced by vaginal lactobacilli, and their association 
with protection against pathogens remains to be verified. 
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1.3.1.6 Biosurfactants 
 
Biosurfactants are amphipathic molecules, which contain both hydrophobic and 
hydrophilic domains. These compounds, which can be proteins, carbohydrates, or 
glycoproteins, are employed by microbes for a variety of purposes, such as emulsification 
of hydrocarbons, quorum-sensing, biofilm regulation, antimicrobial activity, and 
regulation of adhesion and detachment [Rodrigues et al., 2006]. 
Reid et al. reported that numerous lactobacilli strains from gastrointestinal and vaginal 
origin produce biosufactants. Some of these biosurfactants are secreted, whereas others are 
associated with the surface of the bacterium [Reid et al., 1999]. In another study, using the 
extract of surface-associated components from L. jensenii, it was shown that these bacteria 
have biosurfactant activity capable to inhibit the adherence of N. gonorrhoeae to epithelial 
cells in vitro [Spurbeck and Arvidson, 2010]. Therefore, biosurfactants produced by 
lactobacilli could play a significant role in reducing microbial infections, and also should 
be studied further to determine the involvement of these molecules in the inhibition of 
vaginally acquired pathogen colonization. 
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1.4 Common gynecological infections 
 
Pathogen invasion of the lower female reproductive tract may result in local infections, as 
well as widespread to the upper female reproductive tract, potentially leading to fertility 
and pregnancy disorders. A shift in the composition of the vaginal microbiota, which is 
dominated by lactobacilli in homeostatic conditions, is associated with several disorders 
such as bacterial vaginosis, aerobic vaginitis, vulvovaginal candidiasis, urogenital tract 
infections, or sexually transmitted infections, which can coexist and mutually support each 
other by fueling local inflammation in the female reproductive tract. C. albicans, C. 
trachomatis, and human immunodeficiency virus (HIV) are among the infectious agents 
that most significantly affect women’s health worldwide. 
 
1.4.1 Bacterial vaginosis and aerobic vaginitis 
 
Bacterial vaginosis (BV) is a condition characterized by replacement of the normally 
protective Lactobacillus spp. with a massive overgrowth of anaerobic and facultative 
organisms, including G. vaginalis, A. vaginae, Bacteroides spp., Molibincus spp., and 
genital mycoplasmas [Eschenbach et al., 1989; Fredricks and Marrazzo, 2005; Srinivasan 
and Fredricks, 2008]. BV is the most common vaginal disorder of reproductive age women 
and is associated with serious adverse sequelae including infertility, endometritis, and 
pelvic inflammatory disease, spontaneous abortion, as well as an increased risk of 
acquiring HIV, N. gonorrhoeae, C. trachomatis, and other sexually transmitted infections 
[Haggerty et al., 2004; Leitich et al., 2003; Sweet, 1995; Taha et al., 1998; Wiesenfeld et 
al., 2003]. 
 
Aerobic vaginitis (AV) is an alteration in the vaginal microbiota associated with aerobic 
microorganisms; mainly group B Streptococcus, S. aureus, E. coli, and Enterococcus 
[Donders, 2007; Donders et al., 2002]. AV is differentiated from BV mainly by the 
presence of inflammatory response associated with aerobe microorganisms [Cauci, 2004]. 
Interestingly, Donders et al. observed that 20% of women with AV also exhibited an 
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overgrowth of G. vaginalis, indicating that there may be a degree of overlap with BV or 
that the two entities may coexist [Donders et al., 2002]. 
 
1.4.2 Vulvovaginal candidiasis (VVC) 
 
VVC is a common infection compromising the quality of life of many women. Candida 
infection affects 70-75% of women at least once during their lives, whereas 40-50% of 
them experience at least one recurrence and about 5-8% of these women suffer from 
recurrent VVC [Peters et al., 2014]. C. albicans is the most frequent etiologic agent of 
VVC [Workowski et al., 2010] causing almost all acute uncomplicated cases and about 
70% of complicated cases of recurrent VVC. The remaining 30% are caused by C. 
glabrata, C. parapsilosis, C. kruzei, or C. tropicalis [Nyirjesy et al., 1995]. 
Candida has an extraordinary dual lifestyle capacity, which permits to adapt to different 
environmental and host habitats, allowing host-colonization either as a commensal or 
opportunistic pathogen. This duality is due to their morphological capacity to change from 
a round ovoid typical yeast cell (Y) to a hyphal mycelial-growing organism (H). This 
transition is crucial for its pathogenicity. There is sufficient evidence that the Y form is 
predominantly associated with commensalism, while the H form is associated with 
pathogenicity. In the Y form, Candida can be found in the intestine and vagina of more 
than 50% of healthy asymptomatic subjects, whereas the H form is invariably found in 
pathologic specimens obtained from invaded tissues. It remains to be determined whether 
the presence of commensal Candida confers a benefit to the host in terms of balanced 
microbiota composition and maintenance of local homeostasis. However, when tolerance 
mechanisms become defective, the Y form changes into the H form and expresses its 
virulence capacity [Harriott et al., 2010; Wang, 2009]. 
Factors associated with the transition from asymptomatic colonization to symptomatic 
infection may be intrinsic to the host, the environment, the host behavior, or related to the 
organism itself. For instance, diabetes-associated glycosuria and the use of antibiotic and 
estrogen-based drugs may contribute to Candida colonization and infection [Fischer and 
Bradford, 2011; Nyirjesy et al., 2012; Pirotta and Garland, 2006]. Behavioral factors such 
as orogenital sex can facilitate Candida infections [Geiger and Foxman, 1996]. The use of 
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hormonal and contraception methods has also been associated with an increase in incidence 
of VVC [Nyirjesy, 2008]. 
 
Symptomatic C. albicans infections are commonly treated with azole antifungal drugs. 
Since azoles are fungistatic for C. albicans, cells repetitively exposed to these drugs may 
become azole resistant [Coste et al., 2007]. Moreover, elevated healthcare costs due to the 
high incidence of VVC together with the growing problem of antibiotic resistance, urge 
the development of new effective probiotic agents for the prevention and therapy of this 
gynaecological infection [Falagas et al., 2006]. 
 
1.4.2.1 Role of vaginal Lactobacillus against VVC 
 
Although the pathogenesis of VVC remains a controversial issue, it seems that, upon the 
disruption of the balance existing between host and vaginal microbiota, the overgrowth of 
Candida is facilitated. In some studies, VVC was associated either with a reduced number 
of lactobacilli or with species of lactobacilli not producing H2O2 [Hawes et al., 1996; 
Hillier et al., 1992; Vitali et al., 2007]. For example, Vitali and colleagues showed that 
women with VVC hosted reduced numbers of H2O2 producer lactobacilli species (L. 
acidophilus, L. gasseri, and L. vaginalis) and increased numbers of non-H2O2 producer 
bacteria (L. iners) [Vitali et al., 2007]. On the contrary, several studies based on molecular 
methods have shown how vaginal colonization by Candida spp. is more common in women 
with a microbiota dominated by lactobacilli, than the microbial profile associated with 
bacterial vaginosis [Drell et al., 2013; van de Wijgert et al., 2014; van de Wijgert et al., 
2008]. In addition, it was demonstrated that Candida infection did not alter the bacterial 
composition of the microbiota itself, which remained homogeneous and stable over time, 
and possibly dominated by lactobacilli [Biagi et al., 2009; Zhou et al., 2009]. 
In vitro studies reported that lactobacilli exert antagonistic effects on Candida infection. 
Lactobacilli can compete with Candida for nutrients and/or adherence to host epithelial 
cells [Osset et al., 2001; Parolin et al., 2015]. L. acidophilus, L. gasseri, and L. jensenii, 
were shown to coaggregate with C. albicans [Boris et al., 1998]. The production of 
antimicrobial substances produced by specific lactobacilli strains can also prevent VVC, 
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in particular organic acids, H2O2, bacteriocins, and biosurfactants [Okkers et al., 1999; 
Parolin et al., 2015; Velraeds et al., 1998]. 
Some clinical studies supported the effectiveness of orally or locally administered probiotic 
lactobacilli as well. For example, Vujic group treated patients diagnosed with VVC with 
capsules containing probiotics L. reuteri RC-14, L. rhamnosus GR-1, and placebo, for 6 
weeks. Their result showed that the microbiota was restored by 61.5% in the probiotics 
group compared to 26.9% of the placebo group [Vujic et al., 2013]. Comparable results 
were obtained administering vaginal suppositories of Lactobacillus GG twice per day for 
7 days [Hilton et al., 1995]. Moreover, it was also studied the effect of probiotics associated 
with azole in treating recurrent VVC. Martinez et al. evaluated one-month therapy with 
probiotics that were added to a single dose of 150 mg fluconazole. Beneficial effect of 
lactobacilli was observed compared to the patients that received only fluconazole [Martinez 
et al., 2009]. Additionally, De Seta et al. observed that local L. plantarum administered 
intravaginally, together with local clotrimazole, offers potential benefits for resolution of 
vaginal discomfort [De Seta et al., 2014]. 
 
1.4.3 Chlamydia trachomatis infection 
 
The obligate intracellular Gram-negative bacterium, C. trachomatis, is a leading cause 
of sexually transmitted infections (STIs) with more than 100 million new cases per year 
according to global estimates [Senior, 2012]. Strains of C. trachomatis are divided into 
three biovars and are further subtyped by serovar. The trachoma biovar (serovars A–C) is 
the leading cause of non-congenital blindness, the genital tract biovar (serovars D–K) is 
the most prevalent sexually transmitted bacterium, and the lymphogranuloma venereum 
biovar (serovars L1–L3) causes invasive urogenital or anorectal infection [Elwell et al., 
2016]. 
In women, 70–80% of genital tract infections with C. trachomatis are asymptomatic, but 
15–40% ascend to the upper genital tract, which can lead to serious sequelae, including 
pelvic inflammatory disease, infertility, and ectopic pregnancy [Malhotra et al., 2013]. 
Moreover, infection with C. trachomatis has been shown to facilitate the transmission of 
HIV and is also associated with the incidence of cervical cancer [Malhotra et al., 2013]. 
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Although chlamydial infection is treatable with antibiotics, no drug is sufficiently cost-
effective for the elimination of the bacterium, and an effective vaccine has been elusive so 
far [Howie et al., 2011]. 
Chlamydia has a unique cycle of development, alternating between two distinct bacterial 
forms (Figure 4). The elementary bodies (EBs) are infectious but non-dividing. In 
contrast, the reticulate bodies (RBs) are non-infectious but replicative [Moulder, 1991]. 
After attachment and penetration in cells, EBs remain internalized in vacuoles 
permitting the escape to phago-lysosomal fusion. Within these vacuoles, named 
inclusion-forming units, EBs differentiate into RBs after several transformations. Unlike 
EBs, RBs are larger, less compacted, metabolically active, and capable to divide by 
binary fission. Around 18 h post-chlamydial infection, RBs resulting by binary fission 
differentiate into EBs, then EBs are expelled from the cell, either by exocytosis or 
cellular lysis between 48–72 h post-infection [Wyrick, 2000]. 
 
 
Figure 4: The life cycle of Chlamydia trachomatis (from www.cytologystuff.com). 
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1.4.3.1 Lactobacilli and Chlamydia trachomatis infection 
 
Lactobacilli are the predominant microorganisms of the healthy women's vaginal 
microbiota and numerous evidences indicate that the presence of a lactobacilli lacking 
vaginal microbiota facilitates the acquisition of various sexually transmitted diseases, 
including C. trachomatis [Brotman et al., 2010; Hillier et al., 1992; Wiesenfeld et al., 
2003]. 
Despite the importance of a healthy vaginal microbiota in preventing genital infections, 
only a few studies have been focused on the protective effects of vaginal lactobacilli 
towards chlamydial infection. Antagonistic effects by lactobacilli on chlamydial EBs, 
chlamydial absorption to epithelial cells, and intracellular phases of chlamydial 
replication have been demonstrated. However, the molecular mechanisms underlying 
the interactions between Lactobacillus and C. trachomatis in the vaginal environment 
have not yet been elucidated. 
Mastromarino and colleagues investigated the effects of two vaginal strains of 
Lactobacillus (L. brevis and L. salivarius) against C. trachomatis infection on HeLa cells. 
They observed that both vaginal lactobacilli significantly inhibit the replication of C. 
trachomatis, independently of pH variations, inhibiting their adhesion to host epithelial 
cells and their intracellular replication as showed by the significant reduction of Chlamydia 
inclusion forming units in HeLa cells compared to the control. A strong inhibition was 
observed especially when lactobacilli were present during early stages of infection. In 
addition, the inhibitory effect of lactobacilli against Chlamydia infection was dose 
dependent, suggesting that the concentration of lactobacilli in the vagina contributes to 
Chlamydia inhibition. In the same study, the effects of L. brevis and L. salivarius were also 
evaluated against the persistent form of C. trachomatis induced by co-infection with HSV-
2, observing that L. brevis has the ability to inhibit Chlamydia even in the persistent form 
of Chalmydia infection [Mastromarino et al., 2014]. 
Gong et al. investigated the effect of two metabolites produced by lactobacilli (L. crispatus, 
L. gasseri, and L. jensenii) against C. trachomatis infection, lactic acid and H2O2. Their 
results indicate that the anti-Chlamydia activity of lactobacilli is primarily due to their 
ability to acidify the vaginal pH by producing lactic acid. Contrarily, H2O2 production 
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seems to not be relevant for Chlamydia inhibition. The authors suggested various 
mechanisms by which lactic acid may inhibit the development of Chlamydia: (i) lactic acid 
could be involved in the inactivation of Chlamydia EBs surface molecules which represent 
their virulence factors for adhesion and penetration to the host cell; (ii) lactic acid could 
compromise the integrity of the outer membrane by reducing the number of disulphide 
bonds between the protein complexes; (iii) and the entry of hydrogen ions into the 
Chlamydia EBs could alter cellular metabolism, essential for early development of C. 
trachomatis [Gong et al., 2014]. 
Another study investigated the immunomodulatory effect of L. crispatus on HeLa and J774 
cells subjected to C. trachomatis infection by studying the expression of the inflammatory 
cytokines IL-6, IL-8, TNF-α and IL-10. They observed that, L. crispatus specifically 
enhances the expression of the anti-inflammatory cytokine IL-10 and inhibits the 
expression of the pro-inflammatory IL-6, IL-8, and TNF-α cytokines in the host cells. 
These results suggest a potential mechanism by which L. crispatus may protect against 
pathological inflammatory conditions. Additionally, L. crispatus inhibited C. trachomatis 
adhesion and infectivity in human epithelial cells and macrophages [Rizzo et al., 2015]. 
 
1.4.4 Human immunodeficiency virus infection 
 
The human immunodeficiency virus (HIV) is a retrovirus belonging to the family of 
Retroviridae, genus lentivirus. HIV is the etiologic agent of the acquired 
immunodeficiency syndrome (AIDS) that results in extremely variable clinical outcomes, 
such as a severe immunodeficiency accompanied by the establishment of opportunistic 
infections and tumors, organ decay, and central nervous system degeneration. Two 
different HIV viruses exist: HIV-1, the pandemic type, and HIV-2, more represented in 
West Africa [Sharp and Hahn, 2011]. 
As shown in figure 5, the replication cycle of HIV-1 begins with a high affinity binding 
between the HIV gp120 and the receptor CD4 expressed on the target cell surface. CD4 is 
a protein mainly expressed by lymphocytes with ‘helper-inducer’ activity, but it is also 
present on monocytes, macrophages, dendritic cells, Langerhans cells, and some 
circulating and bone marrow-resident hematopoietic progenitors. The interaction CD4-
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gp120 induces a conformational change in the structure of gp120 that leads to the exposure 
of the binding site for another receptor, called co-receptor. There are two main co-receptors 
which HIV gp120 recognizes: CXC-chemokine receptor 4 (CXCR4) or CC-chemokine 
receptor 5 (CCR5) [Rizzuto et al., 1998]. Upon HIV-1 entry into the target cell, the core 
dissolves and a reverse-transcription complex assembles in the cytoplasm allowing the 
reverse transcription of the two identical molecules of ssRNA+ in double stranded DNA 
and then evolves in the pre-integration complex that crosses the nuclear membrane 
[Davenport et al., 2002]. Inside the nucleus, the HIV-1 integrase promotes the insertion of 
the viral DNA in the host cell genome, where it can remain transcriptionally silent for years. 
The establishment of a pool of long-lived latently infected CD4 T cells, called HIV 
reservoir, that is not visible to the immune system and continuously revive the infection 
despite antiretroviral treatment, represent the major obstacle to HIV eradication strategies 
[Chun and Fauci, 1999]. Antigenic stimulation through activation of the T-cell receptor 
signaling or stimulation of the host cell by pro-inflammatory cytokines can lead to 
activation and nuclear translocation of host transcription factors, such as NF-kB, that turn 
to activate or enhance HIV-1 provirus transcription by the host enzyme RNA polymerase 
II [Piret et al., 1995]. When a complete transcript is produced, it translocates to the 
cytoplasm where the synthesis of viral proteins with important regulatory functions takes 
place. The final step of the viral replication cycle occurs on the plasma membrane of the 
host cell. Viral components are transported and anchor to the plasma membrane along with 
the HIV-1 genomic ssRNA+ as the forming virion begins to bud from the host cell. Finally, 
the structural components of HIV assemble to produce a mature virion [Bukrinskaya, 
2004]. These include the molecule p24gag incorporated into the protein core that surrounds 
the viral RNA, also known as capsid. Immunoassays targeting this protein have been 
extensively used to measure HIV-1 replication in in vitro infection assays as well as to 
diagnose HIV-1 infection in vivo. 
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Figure 5. Replication cycle of HIV (from http://www.niaid.nih.gov). 
 
1.4.4.1 HIV infection in female genital tract 
 
The female genital tract mucosa is the portal of entry for several clinically relevant sexually 
transmitted viruses, including HIV. Women appear to be more easily infected with HIV 
than men. Differences in social rank, behavior, sex hormone regulation, and especially 
organization of the mucosal surface appear to be involved [Iwasaki, 2010]. 
Male to female sexual transmission of HIV is mediated by the exposure of genital mucosa 
to infectious virions and/or infected lymphocytes and monocytes present in the semen. The 
ratio of transmissibility of cell-free vs. cell-associated viruses is still uncertain, but it seems 
that both are sources of infections and should be targeted by intervention strategies. 
 
Under normal circumstances, the incidence of HIV transmission from males to females via 
vaginal intercourse is very low, within the range of one productive infection for every 200–
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2000 exposures [Schellenberg and Plummer, 2012]. This can probably be explained, in 
part, by the presence of the protective type II mucosa of the female vaginal epithelium cells 
(see section 1.1). Nevertheless, free HIV virions can infect the female reproductive tract in 
many different ways: (i) free HIV virions and/or infected cells can penetrate the epithelium 
through gaps between the epithelial cells or lesion on the vaginal mucosa layer and reach 
the basal layer where the majority of target cells reside (i.e. CD4 cells); (ii) HIV-infected 
donor cells trapped in the mucus layer can release new virions; (iii) virions can be captured 
by Langerhans cells or other antigen presenting cells, located in the epithelium layer and 
subsequently transferred to target cells in the deeper layers of the mucosa or in lymphoid 
organs (transinfection); (iv) virions can penetrate the epithelium through epithelial cells 
(transcytosis) and infect the underlying CD4 T cells or macrophages; (v) virions can also 
make contact with dendritic cells and subsequently get transported to CD4 T cells [Hladik 
and McElrath, 2008; Iwasaki, 2010; Lederman et al., 2006]. Regardless of the mechanism 
of transmission, the establishment of a founder pool of productively infected CD4 T cells 
in the female reproductive tract precedes for virus dissemination to secondary lymphoid 
organs, as demonstrated in pathogenic animal models of HIV-1 infection [Haase, 2001]. 
 
1.4.4.2 Role of vaginal Lactobacillus in protection against HIV 
 
Lactobacilli have been reported to protect against vaginal transmission of HIV [O'Hanlon 
et al., 2013; Ronnqvist et al., 2006]. Although many hypotheses have been formulated 
regarding the protective effects of lactobacilli, their exact mechanism of HIV inhibition 
remains to be fully elucidated in vivo. These mechanisms seem to involve: (i) direct HIV 
killing by lactic acid, H2O2, bacteriocins, and other inhibitory agents; (ii) maintenance of 
vaginal integrity and competition with pathogens for binding to vaginal epithelium; (iii) 
HIV neutralization by lectin molecules, which are present in lactobacilli surface, that bind 
virus glycoproteins and in this way preventing infection; (iv) and enhancement of the local 
host-immune defenses [Aldunate et al., 2013; Kaewsrichan et al., 2006; Klebanoff and 
Coombs, 1991; Olmsted et al., 2005; Petrova et al., 2013; Pretzer et al., 2005; Reid et al., 
2011]. 
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Generally, the low pH of the vaginal environment, caused mainly by lactic acid, is believed 
to be the main strategy to prevent bacterial and viral infections in the vaginal mucosa. For 
example, cell-free HIV-1is inactivated upon incubation in a solution with pH as low as 5.7 
for 2 h. However, incubation in the same condition did not affect cell-associated viral 
infectivity [Martin et al., 1985; Ongradi et al., 1990]. Other studies showed that the acidic 
environment of the vagina may inhibit the activation of HIV target cells, thus reducing 
their susceptibility to HIV-1 infection. Monocytes, macrophages, and lymphocytes, were 
also found to lose the motility at a pH below 6.0 [Hill and Anderson, 1992; Olmsted et al., 
2005]. Human cervico-vaginal mucus, obtained from donors with normal lactobacilli-
dominated vaginal microbiota efficiently traps HIV by decreasing viral diffusion at low pH 
[Nunn et al., 2015]. Of interest, at pH 4, lactic acid, but not HCl, abolished the negative 
surface charge on HIV without lysing the viral envelope, thus may alter HIV surface 
protein structures and/or possibly inactivate the virus by disrupting the envelope membrane 
and exposing the capsid [Lai et al., 2009]. Taken together, these results support the idea 
that maintaining a low pH in the vaginal lumen by production of lactic acid is important to 
reduce HIV transmission. 
 
The effect of H2O2 on the survival of different sexually transmitted viruses including HIV 
has not been extensively addressed. It was reported that the H2O2-producing strain L. 
acidophilus, was virucidal to HIV in cell line infection assay. The anti-HIV activity was 
not observed when L. acidophilus strain was treated for 15 min at 100 °C or when it was 
replaced by a strain unable to produce H2O2. Additionally, the virucidal effect was inhibited 
by catalase, but not by heat-inactivated catalase [Klebanoff and Coombs, 1991]. Besides 
these results, the effect of H2O2 in vivo has not been studied yet plus the vaginal tract is 
microaerophilic and iron-rich, which raises the question of whether lactobacilli produce 
enough H2O2 amounts to inhibit pathogens in vivo. 
 
Molecules on the cell surface of the vaginal microbiota that directly interact with pathogens 
or host cells are postulated to play a role in the exclusion of bacterial and/or viral pathogens. 
Such interactions could be established via carbohydrate-binding proteins known as lectins, 
which interact specifically with carbohydrates on the surface of pathogens and are highly 
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specific for the ligand of interaction. Lectins on the cell surface of vaginal microorganisms 
could play a role in pathogen exclusion by competitively binding to the same glycans on 
the host surface, thereby blocking adhesion or by binding glycans on the pathogenic 
surfaces, thereby blocking virulence mechanisms such as adhesion and invasion. Some 
lectins, especially the ones highly specific for recognition of mannose (e.g. actinohivin and 
griffithsin) and N-acetylglucosamine residues, have been shown to possess activity against 
HIV by binding of the glycans on the viral envelope and thereby blocking the virus entry 
process. Some of these lectins can inhibit the infection of T cells by cell-free virions 
through binding to the HIV gp120 glycoprotein. They can also block the interaction 
between HIV and the macrophage mannose receptor, thereby preventing the infection of 
macrophages. Additionally, lectins can block the dendritic cell-directed transmission of the 
virus to uninfected T cells [Balzarini, 2007]. Nevertheless, the information on lectins 
encoded by Lactobacillus species and especially vaginal isolates is still limited. 
 
Little is known about the relationship between the vaginal microbiota and the immune 
system. HIV infections are characterized by an increase of pro-inflammatory cytokines and 
pro-inflammatory responses. This has been linked with a disruption of the integrity of the 
vaginal mucosa and consequently further activation of HIV in infected people. Therefore, 
vaginal microbiota that can reduce a pro-inflammatory response could contribute to a 
decreased activation of HIV. For example, in vaginal epithelial multilayers treated with 
TLR agonists, a significant reduction of IL-6 and IL-8 expression after treatment with L. 
crispatus was observed. Additionally, L. crispatus and L. jensenii could induce a 
significant reduction of TNF secretion as well as some pro-inflammatory chemokines 
(MIP-1β and RANTES) [Rose et al., 2012]. Further studies need to address the 
immunomodulatory effect of lactobacilli as well. 
 
1.4.4.3 Human ex vivo tissues to study HIV transmission and pathogenesis 
 
Understanding the mechanisms of HIV-1 transmission requires knowledge of the functions 
and interactions of all immune cells and of the extracellular matrix. Although conventional 
isolated cell lines cultures or peripheral blood mononuclear cells have been useful in many 
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areas of HIV research, interpretations of the results of experiments with these cultures are 
limited by the fact that they do not reproduce the spatial distribution of cells and their native 
communication within the tissue cytoarchitecture. 
 
The human ex vivo tissue system is important for the study of multiple aspects of HIV 
pathogenesis and consist in a raft culture, in which blocks of human tissue are cultured on 
collagen sponges at the air-liquid interface. This ex vivo model of tissue culture developed 
and optimized by Grivel and Margolis is based on the work of Joseph Leighton [Grivel and 
Margolis, 2009; Leighton, 1963] and includes cultures of tonsillar, cervico- vaginal, and 
rectosigmoid tissues. These tissues serve as the first gateway for HIV-1 sexual 
transmission, preserving the specific mucosal cell phenotypes therefore important for 
understanding HIV transmission and pathogenesis. 
 
This ex vivo model has many advantages (Table 1). Upon inoculation ex vivo, human 
tissues support productive HIV infection without exogenous activation and stimulation, 
and retain tissue cytoarchitecture as well as the pattern of expression of key cell surface 
molecules relevant to HIV infection for around 2–3 weeks. Some of the tissue functions 
are preserved in ex vivo, including the ability to release a spectrum of cytokines similar to 
those released in vivo, and the ability of tissue challenged with recall antigens (tetanus or 
diphtheria toxoids) to respond by producing specific antibodies. Ex vivo tissues support 
HIV replication without the artificial stimulation that is necessary for productive HIV 
infection in isolated lymphocytes [Grivel and Margolis, 2009; Lisco et al., 2007]. On the 
other hand, the system of ex vivo tissues have some limitations in the study of infection of 
human pathogens (Table 1), mainly the difficulty of applying many modern investigative 
tools developed for isolated cells to these tissues. For example, although microscopy gives 
subcellular resolution in imaging of single cells, the problem of deep tissue penetration 
beyond a few hundred microns is only partially solved with two-photon excitation 
microscopy [Rubart, 2004]. 
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Advantages Disadvantages 
• Preservation of tissue cytoarchitecture, 
including major lymphocyte subtypes and 
follicular- dendritic cell network. 
• In vivo-like spectrum of cytokine release. 
• Continuous expression of HIV 
coreceptors over 2 week in culture. 
• Support of HIV replication without 
exogenous stimulation or activation. 
• In vivo pattern of replication: HIV 
replicates in both activated and 
nonactivated cells. 
• Other tested human viruses, bacteria and 
parasites readily infect tissues, allowing 
the study of their pathogenesis and 
interactions. 
• Viral movement in the tissue can be 
followed in real time by confocal 
microscopy. 
• Tissues start to deteriorate 
after 3 weeks in culture. 
• Difficulty in monitoring cells 
beyond the depth of confocal 
microscopy (unless cells are 
isolated for analysis). 
• The system does not reflect 
the effects of in vivo 
systemic factors. 
• Labor: multiple blocks of 
tissue are required for every 
experimental condition to 
overcome tissue 
heterogeneity. 
• Donor-to-donor variability 
 
Table 1. Advantages and disadvantages of human tissue ex vivo model [Grivel and 
Margolis, 2009]. 
 
The ex vivo tissues have proved to be useful in studies of the effect of HIV-1 copathogens 
on HIV-1 replication [Grivel et al., 2001; Lisco et al., 2007; Vanpouille et al., 2007] as 
well as in pre-clinical drug testing [Andrei et al., 2011; Vanpouille et al., 2012]. These 
tissues ex vivo have been shown to support productive infection of the following viruses as 
well: herpes virus (HHV)-6, HHV-7, HCMV (HHV-5), HSV-2 (HHV-2), vaccinia virus 
and measles virus [Condack et al., 2007; Grivel et al., 2001; Lisco et al., 2007; Vanpouille 
et al., 2007].  Moreover, this ex vivo system have also been shown to support replication 
of the bacterium Borrelia burgdorferi [Duray et al., 2005] and of the parasite Toxoplasma 
gondii [Sassi et al., 2009]. Recently, these tissues ex vivo were also used to study the role 
of vaginal lactobacilli against HIV-1 [Nahui Palomino et al., 2017]. In summary, the 
explant system of cultured human tissues ex vivo permits the study of normal and 
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pathogenic processes, including the ones caused by human infectious agents, in the context 
of tissue cytoarchitecture under controlled laboratory conditions. 
The technique of culturing human tissue ex vivo to study the pathogenesis of HIV and other 
infectious agents consists of the following steps, briefly: the tonsillar and mucosa layers 
from ecto- and endo-cervix (Figure 6) tissues are cut in blocks of 2 mm3. Cervico-vaginal 
tissue blocks are infected with viral stock. After infection, tissue blocks are washed to 
eliminate the free virions then transferred at the liquid-air interface onto Gelfoam in a 12-
well plate containing RPMI 1640 medium at 1 mL/well supplemented with 15% FBS, 
sodium pyruvate at 1 mM, non-essential amino acids at 1 mM, and antibiotics (gentamicin 
sulfate at 50 µg/mL, amphotericin B at 2.5 µg/mL). Instead, tonsillar tissue blocks are 
placed on collagen sponge gels in 6-well plate, and then tissue blocks are infected with 
viral stock, on top of each block. Cervico-vaginal and tonsillar tissue are incubated at 37°C 
for 12 days, with replacement of culture medium every 3 days. 
 
Figure 6. Preparation of cervico-vaginal and tonsillar tissues for histoculture [Introini et 
al., 2014]. 
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2. AIM OF THE RESEARCH 
 
The vaginal microbiota of healthy reproductive-age women is generally dominated by 
Lactobacillus species [Ravel et al., 2011]. The lactobacilli are considered "health 
promoting" microorganisms since they play an active role in maintaining a proper balance 
of the vaginal microbiota by preventing overgrowth of pathogenic and opportunistic 
microorganisms [O'Hanlon et al., 2013; Ronnqvist et al., 2006]. Indeed, lactobacilli play a 
key role in the prevention of numerous urogenital diseases, such as bacterial vaginosis, 
yeast infections, as well as sexually transmitted infections (STIs) [Cherpes et al., 2003; 
Martin et al., 1999; Taha et al., 1998]. 
 
Vulvovaginal candidiasis (VVC) is a common fungal infection compromising the quality 
of life of numerous women. Candida infection affects 70-75% of women at least once 
during their lives [Peters et al., 2014]. Many lactobacilli are known to inhibit the growth 
of Candida spp. but the mechanisms underlying antifungal activity are still not clearly 
understood. The development of VVC has been associated with either a low number of 
lactobacilli in the vagina or with the presence of H2O2-non-producing Lactobacillus species 
[Goffeng et al., 1997; Vitali et al., 2007]. 
Chlamydia trachomatis is the most common causative agent of bacterial STIs in the world, 
with more than 100 million new cases per year according to global estimates [Senior, 
2012]. About 70% of infections caused by this pathogen remains asymptomatic and 
thereby left untreated, representing a relevant public health problem. If not adequately 
treated, C. trachomatis infection induces pelvic inflammation, cervicitis, endometritis, and 
salpingitis which could cause infertility and ectopic pregnancy [Malhotra et al., 2013]. 
Despite the importance of a healthy vaginal microbiota in preventing genital infections, 
only a few studies have focused on the protective effects of vaginal lactobacilli towards 
chlamydial infection [Gong et al., 2014; Mastromarino et al., 2014; Rizzo et al., 2015], and 
therefore the molecular mechanisms underlying the interactions between Lactobacillus and 
C. trachomatis in the vaginal environment have not yet been elucidated. 
Moreover, the female genital tract mucosa is a portal of entry for several STI viruses, such 
as HIV. Today, women constitute more than half of all people living with HIV [CDC report 
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2017]. A Lactobacillus-dominated microbiota appears to be a biomarker for healthy 
vaginal communities, as changes in the vaginal microbiota, especially shifting away from 
Lactobacillus dominance, are associated with bacterial vaginosis and increased risk of 
acquisition of sexually transmitted infections, in particular HIV [Atashili et al., 2008; 
Gosmann et al., 2017; Mirmonsef and Spear, 2014; Nardis et al., 2013; Petrova et al., 2015; 
Taha et al., 1998]. Nevertheless, the exact mechanisms of HIV inhibition by vaginal 
lactobacilli remain to be fully clarified. 
 
In this context, the aim of this study was to investigate the potential antagonistic effect of 
vaginal lactobacilli toward Candida spp., C. trachomatis, and HIV, which are among the 
infectious agents that most significantly affect women’s health worldwide.  
In particular, from vaginal swabs of healthy premenopausal women, we isolated seventeen 
Lactobacillus strains belonging to 3 species mainly represented in the human vaginal 
microbiota: L. crispatus (BC1-BC8), L. gasseri (BC9-BC14), and L. vaginalis (BC15 -
BC17) [Parolin et al., 2015]. It was evaluated their capacity to produce antimicrobial 
compounds to individuate a possible antimicrobial mechanism of action i.e, production of 
lactic acid, hydrogen peroxide, butyrate. It was studied their fungistatic/fungicidal activity 
against numerous clinical isolates of Candida spp., and their capacity to interfere with yeast 
adhesion to HeLa cells [Parolin et al., 2015]. It has been evaluated the capacity of 
lactobacilli to inhibit the infectivity of C. trachomatis on HeLa cells [Nardini et al., 2016]. 
Moreover, we studied the metabolic profiles of lactobacilli supernatants by 1H-NMR to 
identify active metabolites and to find correlations between metabolism of lactobacilli and 
anti-Candida or anti-Chlamydia effect [Nardini et al., 2016; Parolin et al., 2015]. The 
potential role of vaginal lactobacilli in the mechanisms of transmission and pathogenesis 
of HIV was studied in ex vivo human cervico-vaginal and tonsillar tissues [Nahui Palomino 
et al., 2017]. 
 
A major potential application of this research is the identification of active Lactobacillus 
strains to propose as probiotics for prophylaxis and/or adjuvant therapy for the different 
urogenital disturbances that strongly affect women's health. 
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3. MATERIALS AND METHODS 
 
3.1 Isolation of vaginal lactobacilli and characterization of anti-Candida activity 
 
3.1.1 Isolation and taxonomic characterization of vaginal lactobacilli 
 
Fifteen pre-menopausal Caucasian women, aged between 18–45 years old, were recruited 
for the present study. The women were non-menstruating, with no symptoms of 
reproductive tract infection, and not receiving oral/local antimicrobial therapy within the 
previous 2 weeks. All volunteers provided a written informed consent in accordance with 
the Ethics Committee of the University of Bologna and the institutional review board 
approved the study (52/2014/U/Tess). Mid-vaginal secretions were self-collected by 
women with E-swabs (Copan, Brescia, Italy) and immediately processed for lactobacilli 
isolation. The specimens were coded to assure full anonymousness. 
Lactobacillus clones were isolated onto de Man, Rogosa, and Sharpe (MRS) and Brain-
Heart Infusion (BHI) agar plates (Difco, Detroit, MI), both supplemented with 0.05% L-
cysteine. Plates were incubated anaerobically for 24 h at 37°C in anaerobic jars containing 
GasPak EZ (Becton Dickinson, Sparks, MD). Colonies with different morphologies 
yielding variable rods by microscope observation were selected for glycerol stock 
preparation. Thereafter, genomic DNA was extracted from lactobacilli using DNeasy 
Blood&Tissue Kit (Qiagen, Hilden, Germany) following the protocol “Pretreatment for 
Gram-positive bacteria”. The extracted DNA was amplified with Lactobacillus genus-
specific primers Lac1 (AGC AGT AGG GAA TCT TCC A) and Lac2 (ATT YCA CCG 
CTA CAC ATG) [Walter et al., 2001]. The positive isolates were taxonomically 
characterized to the species level by sequencing the 16S ribosomal RNA (rRNA) gene. 
Briefly, the complete 16S rRNA gene (1.5 kb) was amplified with the universal primers 
27F (AGA GTT TGA TCM TGG CTC AG) and 1492R (TAC GGY TAC CTT GTT ACG 
ACT T) and then sequenced [Lane, 1991]. The obtained sequences were compared with 
the sequences available in the Ribosomal Database Project (RDP, http://rdp.cme.msu.edu/) 
in order to identify the Lactobacillus species [Cole et al., 2009]. The nucleotide sequences 
of the 16S rRNA genes of the Lactobacillus strains BC1 to BC17 have been deposited in 
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the DDBJ nucleotide sequence database (http://www.ddbj.nig.ac.jp/) under accession 
numbers AB976542 to AB976558. 
 
3.1.2 Determination of lactobacilli hydrogen peroxide production 
 
Lactobacillus strains were tested for their ability to produce H2O2 as described by 
Pendharkar et al. [Pendharkar et al., 2013] with slight modifications. Isolates were cultured 
onto MRS agar plate containing 0.25 mg/mL of 3,3’, 5,5’-tetramethylbenzidine and 0.01 
mg/mL of horseradish peroxidase in anaerobic condition for 72 h. Plates were exposed to 
air and based on the time required for the appearance of the blue color, isolates were scored 
as low (>20 min; score 1), medium (10–20 min; score 2), and high (<10 min; score 3) H2O2 
producer strains. Isolates not producing blue coloration were scored as 0. 
 
3.1.3 Preparation of lactobacilli fractions 
 
Lactobacilli were cultured in MRS or BHI broth supplemented with 0.05% L-cysteine. 
Incubation was carried out in anaerobic jars supplemented with GasPak EZ overnight at 37 
°C. The turbidity of lactobacilli cultures was measured spectrophotometrically, considering 
that an optical density (OD600) of 0.4 corresponds to a cell concentration of 108 colony 
forming unit (CFU)/mL. Lactobacilli cultures, corresponding to 5 × 108  CFU/mL, were 
centrifuged at 5,000 × g for 10 min at 4 °C. Supernatants were filtered through a 0.2 µm 
membrane filter to obtain stock of Lactobacillus-conditioned medium (CM). 
Lactobacillus-cell pellet (CP) were washed and resuspended in sterile saline containing 
0.05% L-cysteine to obtain a stock bacterial suspensions of 5 × 108  CFU/mL. 
 
3.1.4 1H-NMR analysis 
 
One mL of Lactobacillus-CM was added to 160 µL of a D2O solution of 3-(trimethylsilyl)-
propionic-2,2,3,3-d4 acid sodium salt (TSP) 6.25 mM set to pH 7.0 by means of a 100 mM 
phosphate buffer. 1H-NMR spectra were recorded at 298 K with an AVANCE III 
spectrometer (Bruker, Milan, Italy) operating at a frequency of 600.13 MHz. To avoid the 
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presence of broad signals arising from slowly tumbling molecules, a T2 filter of 400 echoes, 
separated by an echo time of 400 µs, was applied. The signals were assigned by comparing 
their chemical shift and multiplicity with Chenomx software data bank (Chenomx Inc., 
Canada, ver 8.02). To understand the correlation between the taxonomy/anti-Candida 
activity and metaboloma of lactobacilli, a Principal Component Analysis (PCA) was 
performed. The PCA algorithm calculates and sorts linear combinations of the original 
variables, so to highlight the data structure by means of a low number of orthogonal 
projections (Principal Components). The score-plot is the representation of the samples in 
the generated space and highlights the similarities and differences between the samples. 
 
3.1.5 Evaluation of fungistatic/fungicidal activities of lactobacilli supernatants 
 
All Candida strains used in the present study were isolated from routine diagnostic 
procedures at the Microbiology Laboratory of Sant’Orsola-Malpighi University Hospital 
of Bologna. In particular we used 4 isolates of C. albicans, and 5 isolates of non-C. 
albicans: C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. lusitaniae. Candida 
strains were grown aerobically in Sabouraud dextrose (SD) medium (Oxoid, Basingstoke, 
Hampshire, UK) at 35°C. 
The fungistatic activity of Lactobacillus-CM was determined by broth microdilution test 
in accordance with the European Committee on Antimicrobial Susceptibility Testing 
guidelines (EUCAST, http://www.eucast.org/) with slight modifications. Briefly, from 24-
h Candida cultures were prepared Candida stock suspensions at OD530 of 0.5 MacFarland 
with sterile water. Candida stock suspensions were diluted 1:10 with RPMI 1640 medium 
(EuroClone, Pero, Italy), buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid 
and 2% glucose, in order to obtain a yeast suspension of 1–5 × 105 CFU/mL. Thereafter, 
each well of a flat-bottom microdilution plate was inoculated with 100 µL of yeast 
suspension, subsequently filled with 100 µL of Lactobacillus-CM, and incubated at 35°C 
for 24/48 h. A control well contained 100 µL of sterile MRS medium and 100 µL Candida 
suspension was performed as well. The results were obtained by measuring the absorbance 
at 450 nm. Anti-Candida activity of Lactobacillus-CM was determined by considering at 
least 50% of reduction in growth in comparison to the control. To determine a fungicidal 
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effect, 20 µL of samples from wells exhibiting less than 50% of growth were spotted onto 
SD agar plates and incubated at 35°C for 24/48 h. Fungicidal activity was defined as a 
reduction of at least 3 log10 from the starting inoculum [Pendharkar et al., 2013]. The 
fungistatic/fungicidal activity of metabolites (butyrate, orotate, pyroglutamate, and 
isoleucine), whose concentrations were significantly greater in the supernatant of 
lactobacilli strains with anti-Candida activity, was tested as well. 
 
3.1.6 Adhesion assays 
 
Lactobacillus adherence capacity to HeLa cells was evaluated in tubes containing sterile 
coverslips as previously reported [Mastromarino et al., 2002; Verdenelli et al., 2014] with 
slight modifications. Briefly, one mL of HeLa cell suspension, at a concentration of 5 × 
104 cells/mL, was seeded onto each glass coverslip and incubated in Dulbecco’s minimal 
essential medium (DMEM, EuroClone, Pero, Italy), supplemented with 10% foetal bovine 
serum (FBS), 1% L-glutamine, 100 IU/mL penicillin G, and 100 µg/mL streptomycin at 
37°C in 5% CO2. After 48 h, the cells were washed twice with PBS, added 900 µL of 
DMEM free antibiotics, and treated with 100 µL of Lactobacillus-CP (stock 5 × 108 
bacteria/mL). The tubes were then incubated for 1 h at 37°C. Cell monolayers were washed 
several times in PBS, fixed with May-Grünwald, and stained with Giemsa. The results were 
obtained at light-microscopy (1000×) and HeLa cells were scored according to the number 
of lactobacilli attached, chosen 200 cells randomly. Each adherence assay was conducted 
in duplicate. 
Three types of assays were performed to study the mechanisms of interference of vaginal 
Lactobacillus (CM or CP) with the adherence of Candida on HeLa cells: exclusion, 
competition, and displacement [Osset et al., 2001]. C. albicans 1 was chosen as model 
strain. C. albicans was cultured in BHI broth at 30°C for 18 h under constant shaking. 
Yeast cells were centrifuged at 5,000 × g for 10 min, washed, and resuspended in PBS to 
obtain a stock of 5 × 108 yeasts/mL. In the exclusion assay, 100 µL of Lactobacillus-CM 
or CP (from stock 5 × 108 bacteria/mL) were incubated for 1 h at 37°C on HeLa cells. 
Afterwards, 100 µL of Candida cells (stock of 5 × 108 yeasts/mL) were added and 
incubated for 1 h. In the competition assay, lactobacilli fractions and Candida were 
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inoculated simultaneously onto HeLa cells and incubated for 1 h at 37°C. In the 
displacement assay, Candida cells were inoculated onto HeLa cells for 1 h at 37°C. 
Successively, lactobacilli fractions were added and further incubated for 1 h. Yeast 
adhesion to HeLa cells was assessed by microscopy (400×) after Giemsa staining by 
counting the number of Candida cells attached to 200 randomly chosen HeLa cells. The 
results were expressed as the percentage of C. albicans adhered to each HeLa cell 
compared to the control without lactobacilli fractions (control value 100%). All 
experiments were conducted three times and in triplicate for each experimental condition. 
 
3.1.7 Histone acetylation profile analysis 
 
To study the capacity of lactobacilli to induce histone acetylation on Candida, C. albicans 
1 was chosen as model strain. Log-phase yeast cells were inoculated at an OD600 of 0.5 in 
Lactobacillus-CM or MRS broth (negative control) and incubated at 30°C for 6 h. Sodium 
butyrate (20 mM) was used as positive control; and a culture of S. aureus in MRS was used 
as a representative Gram-positive organism. Histones were extracted from yeast cultures 
as described by Knapp et al. [Knapp et al., 2007] with slight modifications. A volume 
equivalent to 20–40 OD600 units of each culture was collected and subjected to nuclei 
isolation. Nuclei were washed for 15 min with wash buffer (10 mM Tris–HCl, pH 8, 75 
mM NaCl, 30 mM Na-Butyrate, 0.5% NP-40, 1.0 mM PMSF, and 10 µg/mL each of 
protease inhibitors) in ice. Washes were repeated four times. Histones were extracted by 
incubating nuclei in H2SO4 0.4N for 1 h in ice, then precipitated overnight in acetone at -
20°C. Equal amount of histones were loaded to a 15% acrylamide gel and separated by 
SDS-PAGE, then transferred to a nitrocellulose membrane and probed with anti-acetyl 
Lysine primary antibody (Merck Millipore, Darmstadt, Germany) and peroxidase-
conjugated anti-mouse IgG secondary antibody (GE Healthcare, Milan, Italy). Peroxidase 
activity was detected by Westar XT system (Cyanagen, Bologna, Italy). Digital images and 
densitometric analyses were performed by using the GS-800 calibrated densitometer (Bio-
Rad Laboratories, Milan, Italy). For each strain, histone acetylation profile was analyzed 
in triplicate. 
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3.1.8 Statistical analysis 
 
Differences in the metabolome composition were assessed by means of a two-tailed 
unpaired Wilcoxon test, through the homonym function implemented in R computational 
software. Linear correlations between fungistatic/fungicidal activities and metabolome 
were assessed by means of ANOVA test. For the adhesion and interference assays data 
analysis were performed by using ANOVA test (GraphPad Prism version 5.02 for 
Windows, San Diego, CA). Results were expressed as mean ± Standard Error of the Mean 
(SEM). Differences were deemed significant for P values < 0.05 or highly significant for 
P values < 0.01. 
 
 
3.2 Antagonistic effect of vaginal lactobacilli toward Chlamydia trachomatis infection 
 
3.2.1 Preparation of Chlamydia elementary bodies (EBs) 
 
C. trachomatis strain GO/86, serotype D, was used in this study [Finco et al., 2011; 
Marangoni et al., 2015]. This strain was isolated from urethral swab at the Microbiology 
Laboratory of Sant’Orsola-Malpighi University Hospital of Bologna. For the Chlamydia 
EBs preparation, confluent HeLa cells were infected with Chlamydia in DMEM medium 
supplemented with cycloheximide 1 µg/mL, which block cellular macromolecular 
synthesis and thus promote the intracytoplasmic development of Chlamydia, in constant 
agitation at 640 × g for 2 h to facilitate cell penetration, and then incubated at 37°C with 
5% CO2 for 48 h [Mastromarino et al., 2014]. HeLa cells were afterward detached and 
fragmented by sonication. Samples were centrifuged at 500 × g for 10 min at 4°C, and 
supernatants, which contain EBs, were further centrifuged at 40,000 × g at 4°C for 1 h. The 
resulting pellets, containing the purified EBs, were resuspended in sucrose-phosphate-
glutamate 0.2 M, divided into small aliquots, and stored at -70°C. 
 
 
 
 
Chapter 3: Materials and methods 
	 38	
3.2.2 C. trachomatis inhibition test 
 
Chlamydia inhibition experiments were tested using three dilutions of Lactobacillus-CM 
(1:1, 1:10, and 1:100) and three different Lactobacillus-CP concentrations (2.5 × 108, 
2.5 × 107, and 2.5 × 106 CFU/mL). All lactobacilli were cultured in MRS medium and their 
fractions were obtained as described earlier (see Materials and Methods section 3.1.3). 
Lactobacillus-CM and CP (100 µL, 10 µL, 1 µL of stock suspension) were mixed with 
5 × 103 Chlamydia EBs and diluted to 200 µL with sterile PBS. pH values were measured 
in the final volume. The same amount of Chlamydia EBs was used as control after verifying 
the lack of effects exerted by MRS medium on EBs infectivity. Mixes were incubated for 
7, 15, and 60 min at 37°C in 5% CO2 atmosphere, afterward they were centrifuged at 
20,000 × g for 10 min at 4°C. Supernatants were used to infect HeLa cells, grown to 
confluence in individual tubes containing sterile coverslips, in constant agitation at 640 × g 
for 2 h, and then incubated at 37°C with 5% CO2 for 48 h. In order to evaluate the effect of 
both pH and organic/inorganic acids against C. trachomatis infectivity, inhibition 
experiments were also carried out with lactic acid and hydrochloric acid (HCl) solutions at 
different concentrations (10 mM and 50 mM) and pH values (pH 4 and 7). The anti-
Chlamydia effect of orotic acid alone (30 µM) or in combination with lactic acid 
(10/50 mM, pH 4/7) was tested as well. Moreover, in order to address the importance of 
glucose depletion in the inhibition of Chlamydia infectivity, supernatants of L. crispatus 
BC1 and L. gasseri BC13 (dilution 1:1) were added with glucose 30 mM and tested in the 
Chlamydia inhibition experiments. 
C. trachomatis infection was evaluated by direct immunofluorescence, using a monoclonal 
antibody against the chlamydial membrane lipopolysaccharide antigen conjugated with 
fluorescein (Meridian, Cincinnati, OH) [Marangoni et al., 2015]. The results were obtained 
by counting Chlamydia inclusion-forming units (IFU) under epi-fluorescence microscope 
(Eclipse E600, Nikon, Japan). The number of IFU was counted in 30 randomly chosen 
200× microscopic fields. 
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3.2.3 Correlation of metaboloma and anti-Chlamydia activity 
 
To investigate for correlations between anti-Chlamydia activity and metabolome of 
lactobacilli, a PCA model was built on the concentration changes of the identified 
molecules (see section 3.1.4), scaled to unit variance. For each molecule, the correlation 
between the concentration change and the loading value with the component of PCA 
describing a metabolome-activity link was calculated. When the correlation was higher 
than 0.6, a statistically significant difference between groups with high activity (H) and 
low activity (L) was searched by means of a Wilcoxon test, with an accepted Bonferroni-
adjusted P value of 0.05. 
 
3.2.4, Statistical analysis 
 
All statistical analysis was performed by using R computational software, applying the 
non-parametric signed- or matched paired- Wilcoxon rank tests. 1- or 2-tailed tests were 
used as well. Differences were deemed significant for P values < 0.05. Spearman 
correlation was calculated by using GraphPad software Prism version 5.02. 
 
 
3.3 Role of vaginal lactobacilli against HIV-1 replication in human tissues ex vivo 
 
3.3.1 Lactobacillus culture conditions 
 
Fifteen Lactobacillus strains (L. crispatus BC1, BC3–BC8; L. gasseri BC9–BC14; and L. 
vaginalis BC16, BC17) were cultured overnight in modified medium at 37°C in anaerobic 
conditions. This modified medium contained 75% RPMI 1640 medium (GibcoBRL, 
Carlsbad, CA), supplemented with 15% FBS, sodium pyruvate at 1 mM, non-essential 
amino acids at 1 mM, and 25% MRS broth supplemented with 0.05% L-cysteine. 
Lactobacillus fraction (CM or CP) were obtained as described in section 3.1.3. 
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3.3.2 Ex vivo tissue cultures and HIV-1 infection 
 
Human cervico-vaginal tissue explants obtained from routine hysterectomy (National 
Disease Research Interchange, Philadelphia, PA) and tonsillar tissue (Children’s National 
Medical Center, Washington, DC) were dissected and cultured as described in Grivel and 
Margolis [Grivel and Margolis, 2009] with slight modifications. Briefly, the tonsillar and 
mucosa layers from ecto- and endo- cervix tissues were cut in blocks of 2 mm3. Eighteen 
cervico-vaginal tissue blocks were infected with 0.4 mL of viral stock HIV-1BaL (120 
ng/mL p24gag obtained from the Virology Quality Assurance Laboratory at Rush 
University, Chicago, IL) for 2.5 h at 37°C in agitation. After infection, tissue blocks were 
washed three times with PBS and transferred at the liquid-air interface onto Gelfoam (9 
blocks/well) in a 12-well plate containing RPMI 1640 medium at 1 mL/well supplemented 
with 15% FBS, sodium pyruvate at 1 mM, non-essential amino acids at 1 mM, and 
antibiotics (gentamicin sulfate at 50 µg/mL, amphotericin B at 2.5 µg/mL). Twenty-seven 
tonsillar tissue blocks (nine blocks per well in 3 mL of RPMI 1640 medium supplemented 
as above) were placed on collagen sponge gels, and tissue blocks were infected with 7.5 
µL of viral stock, on top of each block. Cervico-vaginal and tonsillar tissue were incubated 
at 37°C for 12 days, with replacement of culture medium every 3 days. 3TC (lamivudine 
at 1 µM) was used as a positive control for HIV-1 inhibition. 
 
3.3.3 Lactobacillus colonization on tonsillar explants and evaluation of tissue cell 
depletion 
 
Tonsillar tissues were colonized with fifteen vaginal Lactobacillus strains (twenty-seven 
blocks per condition) at a starting inoculum of 104 CFU/mL. At day 3 after inoculation 
with bacteria, all tissue blocks were collected and digested with collagenase IV (5 mg/mL; 
GibcoBRL) for 30 min with agitation in a Thermomixer at 900 rpm at 37ºC. Following 
digestion, tissue cells were filtered with 100 µm cell strainers (Corning) and washed with 
50 mL of PBS. Cells were then resuspended in 1 mL of PBS and stained with 1 µL of 
live/dead Fixable Viability Dye eFluor 450 (EF 450, Invitrogen) for 15 min. After 
incubation, cells were washed and diluted in staining buffer (PBS, 1% normal mouse 
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serum, 1% normal goat serum, 1 mM EDTA) and stained with anti-CD3-APC for 20 min. 
After surface staining, cells were permeabilized with the Fix&Perm Cell Fixation and Cell 
Permeabilization Kit (Invitrogen) then stained for 20 min with anti-Bcl2-PE, a 
mitochondrial anti-apoptotic antigen. Data were acquired with a Novocyte flow cytometer 
(ACEA Biosciences, CA) equipped with 405, 488, and 640 nm laser lines using 
NovoExpress version 1.2.4 software (ACEA Biosciences) and analyzed using the same 
software. 
 
3.3.4 HIV-1 infection of human tissues ex vivo treated with Lactobacillus-CM 
 
Cervico-vaginal and tonsillar tissue blocks were cultured in Lactobacillus-CM from six 
Lactobacillus strains (L. crispatus BC3, BC5; L. gasseri BC12, BC13; and L. vaginalis 
BC16, BC17). Tissue blocks were pre-incubated with Lactobacillus-CM undiluted and 
diluted 1:5 with normal medium for 2 h before HIV-1 infection. After HIV-1 infection, 
tissue cultures were kept in the same medium (undiluted or diluted 1:5) for the next 3 days 
of culture, then the medium was replaced with complete RPMI medium every 3 days, and 
the culture was kept until day 12. 
 
3.3.5 Virucidal effect 
 
Virucidal experiments were carried out by treating HIV-1 with Lactobacillus-CP or 
Lactobacillus-CM. HIV-1 viral suspensions at 400 µL were mixed with 100 µL of 
Lactobacillus-CP (stock 5 × 108 CFU/mL), corresponding to a final concentration of 108 
CFU/mL, or 100 µl of undiluted Lactobacillus-CM (corresponding to a final 1:5 dilution) 
or with 100 µL of normal medium (experimental control condition). Cultures under these 
three experimental conditions were then incubated for 60 min at 37°C and centrifuged at 
4,000 × g for 10 min at 4°C. Supernatants were used to infect cervico-vaginal tissue, as 
described above (see section 3.3.2). 
 
 
Chapter 3: Materials and methods 
	 42	
3.3.6 Lactic acid quantification, pH measurement of Lactobacillus-CM, and 
evaluation of their effect on HIV-1 replication 
 
We quantified titers of lactate isomers D and L from overnight-cultured Lactobacillus-CM 
using a lactate quantification assay kit according to the manufacturer’s instructions 
(BioAssay system, EFDLC-100 and EFLLC-100). Isomers D (3 mM), L (23 mM), and D 
+ L (3 mM + 23 mM), corresponding to the average titers found in all undiluted 
Lactobacillus-CM, were tested for HIV-1 inhibition in human cervico-vaginal and 
lymphoid tissues. Isomers D and L at concentrations corresponding to those found in 
dilution 1:5 were also tested in lymphoid tissues. pH values in all Lactobacillus-CM, 
undiluted or diluted 1:5, were measured as well. Furthermore, in order to evaluate the effect 
of low pH on HIV-1 replication in tissues ex vivo, as measured in Lactobacillus-CM 
(undiluted average around pH 4 and diluted 1:5 up to pH 6.9), we evaluated HIV-1 
infectivity in ex vivo tissue at pH 4 and pH 6.9, buffering the medium with HCl. 
 
3.3.7 Evaluation of HIV-1 replication 
 
HIV-1 replication on tissue was evaluated by measuring the levels of p24gag in tissue culture 
medium using a dynamic immunofluorescent cytometric bead assay as described by 
Biancotto et al., [Biancotto et al., 2009]. 
 
3.3.8 Statistical analysis 
 
All statistical analyses were performed using ANOVA test GraphPad Prism version 7 
(GraphPad Prism software Inc., San Diego, CA). Results were deemed significant for p 
values < 0.05. 
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4. RESULTS 
 
4.1 Isolation of vaginal lactobacilli and characterization of anti-Candida activity 
 
4.1.1 Taxonomy of vaginal lactobacilli and production of antimicrobial compounds 
 
Seventeen Lactobacillus strains belonging to 3 species mainly represented in the human 
vaginal microbiota were isolated from vaginal swabs of 15 healthy premenopausal women. 
The Lactobacillus isolates were taxonomically identified to species level by sequencing 
the 16S rRNA gene: 8 isolates belong to L. crispatus (BC1-BC8), 6 isolates to L. gasseri 
(BC9-BC14), and 3 isolates to L. vaginalis (BC15-BC17) (Table 2). 
 
 
 
Table 2. Characterization of the vaginal lactobacilli: taxonomy, pH of cultural 
supernatants, and production of antimicrobial compounds. H2O2 production was scored 
as low (>20 min; score 1), medium (10–20 min; score 2), and high (<10 min; score 3). 
Lactate and butyrate were measured in Lactobacillus-CM by 1H-NMR analysis. *nd: not 
determined. 
 
Species Strain pH H2O2 
(score) 
Lactate 
(mM) 
Butyrate 
(mM) 
L. crispatus BC1 3.93 3 2.91 3.48 x 10-1  
L. crispatus BC2 4.13 3 6.83 0.00 
L. crispatus BC3 4.21 1 9.45 0.00 
L. crispatus BC4 3.87 1 3.32 3.54 x 10-1 
L. crispatus BC5 3.70 2 5.10 1.25 x 10-1 
L. crispatus BC6 4.03 2 7.87 8.33 x 10-1 
L. crispatus BC7 3.91 1 1.42 1.35 x 10-2 
L. crispatus BC8 4.08 1 3.05 4.64 x 10-1 
L. gasseri BC9 3.90 2 4.75 0.00 
L. gasseri BC10 4.54 3 9.40 0.00 
L. gasseri BC11 4.20 3 1.46 0.00 
L. gasseri BC12 4.17 3 9.47 0.00 
L. gasseri BC13 3.87 1 1.62 1.84 x 10-2 
L. gasseri BC14 4.74 nd* 3.63 1.00 x 10-2 
L. vaginalis BC15 3.95 1 4.74 6.42 x 10-1 
L. vaginalis BC16 4.59 1 2.44 0.00 
L. vaginalis BC17 4.28 3 2.34 3.27 x 10-1 
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To characterize the antimicrobial properties of the vaginal lactobacilli isolated in this study, 
we measured the pH of Lactobacillus-CM, production of H2O2, lactate, and butyrate (Table 
2). The pH of the lactobacilli supernatants was in the range 3.7–4.7, showing the ability of 
all lactobacilli strains to maintain an acidic environment. H2O2 was produced by the totality 
of the strains. The levels of H2O2 production did not seem related to a particular species. 
The strongest H2O2-producers (score 3) were L. crispatus (BC1, BC2), L. gasseri (BC10-
BC12), and L. vaginalis BC17. Lactobacillus gasseri BC14 was not tested for H2O2 
production since its incapacity of growing on MRS agar plates and in BHI agar plates 
tetramethylbenzidine and horseradish peroxidase precipitated as crystals. Lactate was 
produced by all isolates at concentrations ranging from 1.42 to 47.4 mM. The highest 
capacity to produce lactate was showed by L. vaginalis species, in particular L. vaginalis 
BC15. Butyrate was produced by 9 out of 17 lactobacilli at concentrations ranging from 
1.00 x 10-2 to 8.33 x 10-1 mM. The highest levels of this metabolite were found in the 
supernatants of L. crispatus BC6 and L. vaginalis BC15. Production of butyrate appeared 
to be negligible in L. gasseri species and variable in the other two species. 
 
4.1.2 Fungistatic and fungicidal activities of vaginal lactobacilli 
 
The fungistatic and fungicidal activities of Lactobacillus-conditioned medium (CM) were 
evaluated against 4 clinical isolates of C. albicans and 5 species different than C. albicans 
(C. tropicalis, C. krusei, C. parapsilosis, C. glabrata, and C. lusitaniae) (Figure 7). In 
general, Lactobacillus strains were more active toward C. albicans isolates. On the other 
hand, none of the Lactobacillus strains showed activity against C. krusei and C. 
parapsilosis. The strains that showed the broadest spectrum of anti-Candida activity were 
L. crispatus (BC1, BC4, BC5) and L. vaginalis BC15, since they exerted fungicidal activity 
against all strains of C. albicans and C. lusitaniae. In addition, L. crispatus BC1 and L. 
vaginalis BC15 exhibited fungistatic activity towards C. tropicalis and C. glabrata, 
showing the broadest anti-Candida profile. Lactobacillus crispatus BC4 and BC5 were 
fungistatic towards eighter C. tropicalis or C. glabrata. A good spectrum of activity was 
also shown by L. crispatus BC7 that was fungicidal for all C. albicans isolates and 
fungistatic for C. tropicalis and C. glabrata. Among the remaining lactobacilli, exhibiting 
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an intermediate profile of antifungal activity, the most interesting were L. crispatus BC3 
and BC6 (fungicidal against 3 species of C. albicans and C. lusitaniae), and L. crispatus 
BC2 (fungicidal against 2 species of C. albicans and C. lusitaniae). The less active strains 
were L. gasseri (BC10, BC11, BC14) and L. vaginalis BC16. Lactobacillus vaginalis 
BC16 exerted a fungistatic activity only towards C. albicans 1 while L. gasseri BC14 was 
fungistatic for C. albicans 1 and C. glabrata. Lactobacillus gasseri BC10 and BC11 
showed no fungistatic/fungicidal activity towards any of Candida isolates. 
 
In summary, the anti-Candida activity of Lactobacillus-CM was strongly associated with 
L. crispatus spp. being highly or moderately active against Candida. Conversely, poor anti-
yeast activity was exhibited by L. gasseri spp. Notably, L. vaginalis spp. showed extremely 
variable profiles of antifungal activity, comprising one highly active strain, one with an 
intermediate spectrum, and one poorly active. 
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Figure 7. Fungistatic/fungicidal activity of Lactobacillus strains against Candida 
isolates. The fungistatic activity of Lactobacillus-CM was determined by broth 
microdilution test (EUCAST, http://www.eucast.org/). Fungistatic activity of 
Lactobacillus-CM was determined by considering at least 50% of reduction in growth 
compared to the control. To determine a fungicidal effect, samples exhibiting less than 
50% of growth were spotted onto SD agar plates. Fungicidal activity was defined as a 
reduction of at least 3 log10 from the starting inoculum. Fungicidal (black cells), fungistatic 
(grey cells), and no anti-fungal activity (white cells). 
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4.1.3 Lactobacilli metabolome correlates with taxonomy and fungistatic/fungicidal 
activity 
 
Lactobacillus-CM of each lactobacilli strain was analyzed by 1H-NMR. We identified 40 
molecules mainly belonging to the families of aminoacids, organic acids monosaccharides, 
ketones, and alcohols (Table 3). 
 
Strain 
Molecule 
2-
Hydro
xybuty
rate 
Leuc
ine 
Isole
ucin
e 
Vali
ne 
Ethan
ol 
Propyl
ene 
glycol 
Alanin
e 
Valera
te 
Acetat
e 
Methi
onine 
Acetoi
n 
Aceto
ne 
Pyru
vate 
Sarc
osin
e 
Aspart
ate 
N.N-
dimet
hylgly
cine 
Creati
ne 
Creati
nine 
Cholin
e 
sn-
glycer
o-3-
phosp
hochol
ine 
BC1 -0.66 0.86 0.41 0.55 0.08 0.01 1.01 -0.09 -29.21 0.12 0.03 0.64 0.90 0.15 -0.02 0.00 -0.19 -0.30 0.01 -0.20 
BC2 -0.37 1.20 0.38 0.51 0.05 0.02 1.00 -0.07 -23.14 0.16 0.02 0.46 0.70 0.15 -0.01 0.00 -0.25 -0.29 0.02 -0.18 
BC3 1.53 3.44 1.10 0.89 0.47 -0.01 0.83 -0.20 -17.86 0.22 0.12 0.03 0.77 0.11 -0.01 0.09 -0.35 -0.48 -0.01 -0.20 
BC4 -0.72 0.57 0.23 0.35 0.15 0.00 0.61 0.10 -27.97 0.20 0.01 0.42 0.17 0.10 -0.03 0.00 -0.30 -0.33 0.04 -0.22 
BC5 -0.27 1.28 0.24 0.33 0.00 0.01 0.65 0.12 -23.89 0.20 0.02 0.33 0.33 0.10 -0.03 0.00 -0.34 -0.37 0.04 -0.15 
BC6 0.15 0.94 0.23 0.26 -0.02 0.03 0.03 0.42 -26.06 0.16 -0.01 0.01 0.31 0.12 -0.02 -0.01 -0.36 -0.42 -0.01 -0.18 
BC7 1.31 3.40 0.74 0.63 0.49 0.00 1.00 -0.20 -32.95 0.07 0.09 1.80 0.15 0.08 -0.03 0.00 -0.31 -0.46 0.04 -0.17 
BC8 2.10 3.35 0.91 0.84 0.21 0.03 0.40 0.48 -30.98 0.24 0.02 0.00 0.12 0.14 -0.03 0.00 -0.33 -0.40 -0.01 -0.22 
BC9 -0.92 0.66 0.34 0.55 0.51 0.01 1.30 -0.27 -36.67 0.20 1.98 2.95 0.17 0.16 -0.02 0.00 -0.16 -0.35 0.03 -0.23 
BC10 -0.78 0.74 0.52 0.57 0.13 0.02 0.90 0.04 -22.91 0.26 0.00 0.36 0.25 0.13 0.00 0.00 0.30 -0.08 0.00 -0.14 
BC11 -0.48 1.34 0.63 0.69 0.01 0.02 0.86 0.06 -24.80 0.27 0.02 0.41 0.40 0.14 0.01 0.00 -0.36 -0.36 0.01 -0.21 
BC12 -0.46 1.35 0.77 0.83 0.07 0.01 1.02 0.13 -32.12 0.28 0.06 0.84 0.42 0.14 -0.02 0.00 -0.34 -0.34 0.01 -0.24 
BC13 -0.47 1.48 0.58 0.89 0.16 0.01 1.56 0.18 -30.40 0.32 0.01 0.53 0.19 0.14 -0.03 0.12 -0.27 -0.31 0.05 -0.20 
BC15 0.96 0.50 0.43 0.07 10.10 0.14 -0.18 0.19 -5.22 -0.14 0.00 -0.06 0.29 0.02 0.02 0.04 -0.23 -0.37 -0.16 -0.18 
BC16 1.67 1.96 0.83 0.69 36.18 0.33 1.33 0.07 -11.55 -0.06 -0.01 0.01 0.25 0.03 0.03 0.08 0.13 -0.03 -0.07 -0.21 
BC17 2.00 2.93 0.95 0.76 43.74 0.22 0.31 0.46 -13.63 0.07 -0.01 -0.01 0.14 0.08 0.00 0.00 0.11 -0.12 -0.02 -0.15 
Strain 
Molecule 
Fructo
se 
Pyrogl
utama
te 
1,3-
dihy
drox
yace
tone 
Lactos
e4.45 
Glucos
e 
Ribo
se Uracil 
2-
deoxy
uridin
e 
Uridin
e 
Adeno
sine 
Inosin
e 
Orot
ate 
N-
Acetyl
tyrosi
ne 
Tyrosi
ne 
Trypt
ophan 
Phenyl
alanin
e 
Cytidi
ne 
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BC1 -0.13 -0.16 1.11 0.60 -28.54 0.14 -0.09 -0.07 -0.01 0.15 -0.11 0.03 -0.47 0.03 -0.15 -0.43 -0.06 -0.16 2.91 0.35 
BC2 -0.07 0.25 0.79 0.73 -20.89 0.12 -0.06 -0.06 -0.02 0.11 -0.09 0.03 -0.05 0.41 -0.17 -0.04 -0.06 -0.17 6.83 0.00 
BC3 -0.01 -0.49 0.96 0.34 -18.98 0.11 -0.05 -0.06 -0.01 0.07 -0.06 0.01 -0.68 0.40 -0.65 0.13 -0.06 -0.09 9.45 0.00 
BC4 -0.02 -0.20 0.79 0.79 -24.02 0.08 -0.06 -0.05 -0.01 0.08 -0.09 0.03 -0.11 0.47 -0.02 0.17 -0.07 -0.17 3.32 0.35 
BC5 -0.11 -0.43 0.76 0.76 -19.47 0.06 -0.05 -0.05 -0.01 0.05 -0.08 0.02 -0.54 0.11 -0.07 0.16 -0.06 -0.16 5.10 0.13 
BC6 0.11 -0.63 0.56 0.27 -19.16 0.05 -0.07 -0.04 0.01 0.05 -0.06 0.02 -0.07 0.13 -0.20 0.13 -0.05 -0.16 7.87 0.83 
BC7 0.13 -0.17 0.79 0.60 -23.64 0.09 -0.04 -0.06 -0.01 0.06 -0.09 0.02 -0.04 0.24 -0.12 -0.04 -0.07 -0.17 1.42 0.01 
BC8 -0.02 -0.71 0.91 -2.11 -19.66 0.06 -0.09 -0.05 -0.01 0.05 -0.06 0.02 -0.13 0.23 -0.30 0.03 -0.05 -0.17 3.05 0.46 
BC9 0.13 1.28 1.28 1.20 -26.73 0.00 -0.06 -0.03 -0.03 0.04 -0.04 0.01 -0.41 0.03 -0.18 -0.29 -0.06 -0.14 4.75 0.00 
BC10 -0.02 -0.27 0.92 0.44 -6.11 0.04 0.05 -0.04 -0.02 0.01 -0.05 0.01 -0.17 0.63 -0.21 0.75 -0.04 -0.19 9.40 0.00 
BC11 0.04 -0.23 1.39 0.52 -18.10 0.04 -0.01 -0.06 -0.03 0.03 -0.05 0.00 -0.21 0.62 -0.25 0.64 -0.06 -0.16 14.60 0.00 
BC12 -0.02 -0.71 1.19 0.50 -21.40 0.06 0.04 -0.08 -0.02 0.06 -0.02 0.00 -0.15 0.53 -0.24 0.52 -0.07 -0.16 9.47 0.00 
BC13 -0.03 -0.82 1.92 1.16 -28.83 0.01 -0.10 -0.04 -0.04 -0.01 -0.01 0.01 -0.59 0.70 -0.10 -0.18 -0.07 -0.13 1.62 0.02 
BC15 -0.07 -0.60 0.37 -1.09 -26.41 0.03 -0.09 0.03 -0.03 0.00 -0.09 0.03 0.08 -0.22 -0.09 -1.30 -0.05 -0.06 47.40 0.64 
BC16 -0.14 0.05 0.14 -0.30 -16.41 0.05 -0.08 -0.01 -0.01 -0.01 -0.04 0.00 -0.15 0.45 -0.60 -0.10 -0.03 0.15 24.40 0.00 
BC17 -0.12 0.11 0.39 -2.08 -20.81 0.03 -0.09 -0.02 -0.02 -0.02 -0.07 0.01 -0.57 0.10 -0.28 0.18 -0.03 -0.09 23.40 0.33 
 
Table 3. Metabolites identified by 1H-NMR in Lactobacillus-CM.	Values are expressed 
as mmol/l. L. gasseri BC14 was not included in the metabolomics analysis because the 
metabolic profile of BHI supernatant could not be compared with the metabolic profiles of 
MRS supernatants.	
 
On the entire set of metabolites a Principal Component Analysis (PCA) and the distribution 
of Lactobacillus strains in relation to the pool of metabolites was performed (Figure 8). 
This multivariate analysis showed two interesting correlations: (i) metabolome versus
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taxonomy (PC1, expl. var 28%) and (ii) metabolome versus fungistatic/fungicidal activity 
(PC2, expl. var 17.4%). Figure 8A shows the distribution of the three different species of 
lactobacilli (L. crispatus, L. gasseri, and L. vaginalis) in relation to the metaboloma. These 
correlations were best visualized by means of box blots representing the distribution of 
Lactobacillus species (Figure 8B). Figure 8C shows the relation between 
fungistatic/fungicidal activity and metabolome. In general, metabolic profiles varied 
according to the Lactobacillus taxonomy. In particular, metabolome of L. vaginalis 
significantly differed from those of L. crispatus and L. gasseri (p < 0.05). The highest 
metabolic heterogeneity was observed within L. crispatus, as demonstrated by the width of 
the corresponding boxplot (Figure 8B). Moreover, the fungistatic/fungicidal activities of 
lactobacilli were related to their metabolome. Strains with different anti-Candida activity 
were clearly separated in the vertical direction: the most active strains occupied the lower 
positions while the less active strains were placed in the upper areas of the two-dimensional 
space represented by the biplot (Figure 8C). 
 
 
Figure 8. Lactobacilli metabolome correlation with taxonomy and fungistatic/fungicidal 
activity. (A) Biplot of a PCA performed on the total metabolites identified by 1H-NMR in 
Lactobacillus-CM. Expl. Var, explained variance. (B) Box plots representing the 
distribution of Lactobacillus species in relation to the metabolome. Lines within the boxes 
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indicate the median values of the samples groups corresponding to L. crispatus, L. gasseri 
and L. vaginalis species. (C) Box plots representing the distribution of 
fungistatic/fungicidal activity towards C. albicans and C. non-albicans in relation to the 
metabolome. Lines within the boxes indicate the median values of the samples groups 
corresponding to the different activity scores (0-4 for C. albicans; 0-5 for C. non-albicans). 
Each box represents the interquartile range (25–75th percentile). The bottom and top bars 
indicate the 10th and 90th percentiles, respectively. Outlier values are indicated (BC10 
and BC15). 
 
Next, we searched which metabolites varied in relation to antifungal activity through 
Wilcoxon univariate statistical test. We identified 4 metabolites (butyrate, orotate, 
pyroglutamate, and isoleucine) whose concentrations significantly increased (p < 0.05) in 
Lactobacillus-CM of active strains. Fungistatic/fungicidal activities of these compounds 
(alone or in combination) were evaluated, but no anti-Candida activity was observed. 
However, we cannot exclude a synergistic action of these metabolites in the more complex 
cultural medium where other bacterial molecules may act as enhancers. 
 
4.1.4 Vaginal lactobacilli interfere with C. albicans adhesion to HeLa cells 
 
The adhesion of vaginal lactobacilli to epithelial tissue represents the first defense barrier 
to prevent undesirable microbial colonization [Donnarumma et al., 2014; Rizzo et al., 
2013; Verdenelli et al., 2014]. Thus, all Lactobacillus strains were examined for their 
adherence ability to HeLa cells (Figure 9). Adherence capacity varied among the 
lactobacilli analyzed, in a range between 0.07 ± 0.03 and 17.68 ± 0.78 (mean ± SEM) 
bacteria/cell. In particular, L. crispatus (BC1, BC3) and L. gasseri BC8 were the most 
adhesive strains (> 10 bacteria/cell). Lactobacillus crispatus BC2 and L. vaginalis BC15 
showed an intermediate adhesiveness (2–10 bacteria/cell). The remaining strains showed 
low adherence capacity (< 2 bacteria/cell). These data demonstrate that the adhesive 
properties are strain-specific rather than species-specific, varying considerably between 
strains of the same species. 
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Figure 9. Vaginal lactobacilli adhesion capacity to HeLa cells. Confluent HeLa cells were 
treated with Lactobacillus-CP at a concentration 5 × 108 bacteria/mL for 1 h at 37°C. Cell 
monolayers were washed, fixed with May-Grünwald, and stained with Giemsa. The results 
were obtained at light-microscopy (1000×) and HeLa cells were scored according to the 
number of lactobacilli attached, chosen 200 cells randomly. The results were expressed as 
average number of adherent bacteria per cell. Error bars represent SEM. 
 
To verify the antagonist effect of lactobacilli toward C. albicans, the influence of 
Lactobacillus (CM or CP) on the adhesion capacity of the yeast to HeLa cells was 
investigated (Figure 10). Three mechanisms of adhesion interference were examined: 
exclusion (Figure 10A), competition (Figure 10B), and displacement (Figure 10C). Ten 
lactobacilli strains out of seventeen: L. crispatus (BC1, BC2, BC5, BC7, BC8), L. gasseri 
(BC9, BC10, BC11, BC12), and L. vaginalis BC16 significantly reduced the adhesion of 
C. albicans through all three mechanisms. The inhibitory effect was exerted in some cases 
by Lactobacillus-CP and in other cases by Lactobacillus-CM. Particularly, L. crispatus 
BC2, L. gasseri BC10, and L. gasseri BC11 interfered Candida adhesion by both 
Lactobacillus-CP and CM, being these strains the most effective in terms of interference 
on pathogen adhesion. Only three strains did not exercise any effect on C. albicans 
adhesion: L. gasseri BC13, L. gasseri BC14, and L. vaginalis BC17. The remaining strains 
showed an intermediate effect on yeast adhesion through one or two of these mechanisms. 
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Figure 10. Interference of C. albicans adhesion to HeLa cells by vaginal lactobacilli. 
Exclusion (A), competition (B), and displacement (C). The results were expressed as 
percentages of adherent yeasts per HeLa cell and compared to the control (free of 
lactobacilli). Yeast adhesion to HeLa cells was assessed by microscopy (400×) after 
Giemsa staining by counting the number of Candida cells attached to 200 randomly chosen 
HeLa cells. The control value was taken as 100% of adhesion (black bars). Green and grey 
bars show the adhesion of C. albicans in presence of Lactobacillus-CP and CM, 
respectively. Statistical significance was determined at p < 0.05*, p < 0.01**, and p < 
0.001***. Error bars represent SEM. 
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4.1.5 Lactobacilli effects on C. albicans histone acetylation 
 
Both the yeast histone deacetylase (HDAC) inhibition and the consequent histone hyper-
acetylation, represent a novel mechanism by which Candida growth and adhesion to the 
host epithelium can be reduced [Simonetti et al., 2007; Smith, 2002]. Thus, we evaluated 
whether the anti-Candida activity and Candida adhesion interference exerted by the 
lactobacilli could be associated to this mechanism. Acetylation profiles of H2/H3 and H4 
histones of C. albicans 1 were evaluated for all Lactobacillus-CM, except for L. gasseri 
BC14. We attributed hyper-acetylating ability of H2/H3 or H4 histones at least equal to 
those induced by sodium butyrate, used as positive control (Table 4). The majority of 
lactobacilli induced histone hyper-acetylation. Histones H2/H3 were hyper-acetylated by 
12 strains and histone H4 by 11 strains. Both L. gasseri BC13 and L. vaginalis BC17 were 
the only strains that did not induce histone acetylation. Interestingly, these lactobacilli 
showed no fungicidal activity towards C. albicans 1 and also any inhibitory effect on the 
adhesion of the pathogen. These data suggest that the complete lack of inhibition of 
HDACs could compromise antifungal activity of lactobacilli. 
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Stimulus 
Histone 
acetylation 
H2/H3 H4 
NaBu + + 
S. aureus - - 
L. crispatus BC1 - + 
L. crispatus BC2 + - 
L. crispatus BC3 + - 
L. crispatus BC4 + + 
L. crispatus BC5 + - 
L. crispatus BC6 + + 
L. crispatus BC7 + + 
L. crispatus BC8 + + 
L. gasseri BC9 + + 
L. gasseri BC10 + + 
L. gasseri BC11 - + 
L. gasseri BC12 + + 
L. gasseri BC13 - - 
L. vaginalis BC15 + + 
L. vaginalis BC16 + + 
L. vaginalis BC17 - - 
 
Table 4. Acetylation of C. albicans histones H2/H3 and H4 by Lactobacillus-CM. Yeast 
cells were inoculated in Lactobacillus-CM and incubated at 30°C for 6 h. Histones were 
extracted from yeast cultures and histone acetylation profile was analyzed by western blot. 
Sodium butyrate (NaBu, 20 mM) was used as a positive control. (+) Acetylation ³ NaBu. 
(-) Acetylation < NaBu. 
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4.2 Antagonistic effect of vaginal lactobacilli toward C. trachomatis infection 
 
4.2.1 Effects of Lactobacillus-CM on C. trachomatis infectivity 
 
To investigate the potential antagonist role of vaginal lactobacilli against C. trachomatis, 
we evaluated the ability of seventeen Lactobacillus strains to abolish infectivity of 
Chlamydia EBs, before they interact with cellular host receptors. 
Three different dilutions (1:1, 1:10, 1:100) of Lactobacillus-CM were tested at three 
different time points (7, 15, 60 min) (Figure 11). After the challenge with Lactobacillus-
CM, the capacity of C. trachomatis EBs to infect HeLa cells was assessed by 
immunofluorescence. 
At the highest supernatant concentration (dilution 1:1), the majority of Lactobacillus 
strains significantly reduced C. trachomatis EB infectivity on HeLa cells. Ten 
Lactobacillus strains: L. crispatus (BC1-BC8), L. gasseri BC9, and L. vaginalis BC15 
completely abolished the infectivity of Chlamydia EBs at any time point. The supernatants 
of five Lactobacillus strains: L. gasseri (BC11-BC14) and L. vaginalis BC16 decreased C. 
trachomatis infectivity at any contact time, inhibiting completely after a long-term 
exposure (60 min). Lactobacillus vaginalis BC17 showed a moderate anti-Chlamydia 
activity at short contact time (7 min) and L. gasseri BC10 did not exert any inhibitory 
activity (Figure 11A). Supernatants of L. crispatus (BC2, BC6, BC7) diluted 1:10 were 
still capable to reduce significantly C. trachomatis infectivity at all three time points. 
Lactobacillus crispatus (BC1, BC3-BC5, BC8), L. gasseri (BC9, BC11-BC13), and L. 
vaginalis (BC16, BC17) retained the anti-Chlamydia activity at short time points (7 and/or 
15 min). Lactobacillus gasseri (BC10, BC14) and L. vaginalis BC15 did not alter 
Chlamydia EBs infectivity (Figure 11B). At the lowest concentration (dilution 1:100), 
eleven Lactobacillus strains: L. crispatus (BC2-BC6, BC8), L. gasseri (BC9, BC11, 
BC13), and L. vaginalis (BC16, BC17) decreased C. trachomatis infectivity when applied 
for short contact times, while none of the Lactobacillus strains were effective after 60 
minutes of exposure. L. crispatus (BC1, BC7) and L. gasseri BC12 supernatants did not 
exert any inhibitory activity against C. trachomatis EBs (Figure 11C). 
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In general, L. crispatus supernatants were the most active strains in counteracting C. 
trachomatis infectivity, as all of them abrogated Chlamydia inclusions at the highest 
concentration (1:1), and retained their effect at the intermediate (1:10) and lowest (1:100) 
concentrations, especially L. crispatus BC6 and BC8 strains. Six strains (BC2-BC6, BC8) 
out of eight belonging to L. crispatus species maintained a good activity even at 1:100 
concentrations; indeed, they caused a significant reduction of Chlamydia infectivity for at 
least one time point. Among L. gasseri and L. vaginalis strains, heterogeneous activity 
profiles have been found, especially at the highest concentration: L. gasseri BC9 and L. 
vaginalis (BC15, BC16) supernatants were very effective in C. trachomatis inhibition, in 
contrast to L. gasseri BC10 and L. vaginalis BC17 which showed no Chlamydia inhibition. 
 
The inhibitory activity of lactobacilli supernatants towards C. trachomatis was strictly 
concentration-dependent, being fifteen Lactobacillus-CM (out of seventeen) effective in 
reducing EBs infectivity at the highest concentration, whereas only eleven retained a 
certain efficacy after 1:100 dilution. Notably, at the highest concentration, lactobacilli 
culture supernatants were found to have pH values comprised in the range 3.71-5.28 (pH 
mean value 4.19±0.42). On the contrary, diluted lactobacilli supernatants showed pH 
values, in the range 4.3-7.15 (pH mean value 5.84±0.86) for the dilution 1:10, and in the 
range 6.76-7.31 (pH mean value 7.08±0.15) for the dilution 1:100. This finding indicated 
a strict link between acidity and the ability to inactivate Chlamydia EBs. Indeed, pH values 
of culture supernatants were positively correlated with Chlamydia IFU/field median 
values, showing a Spearman coefficient of 0.7486 (two-tailed p = 9.7357×10-29). Moreover, 
both at the intermediate and lower concentration Lactobacillus-CM exhibited higher 
efficacy when applied for short contact times (7 and/or 15 min). 
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Figure 11. Effect of Lactobacillus-CM on C. trachomatis infectivity. Experiments were 
performed with different dilutions of Lactobacillus-CM: 1:1 (A), 1:10 (B) and 1:100 (C), 
and different time points: 7 minutes (white bars), 15 minutes (grey bars), and 60 minutes 
(black bars). Chlamydia trachomatis infectivity was expressed in terms of percentage of 
inclusions forming units (IFU)/field compared to control. The results were expressed in 
percentage compared with control, taken as 100% (dotted bars). Bars represent median 
values and error bars represent median absolute deviations. Statistical significance was 
calculated vs control. * p < 0.05. 
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4.2.2 Effects of Lactobacillus-CP on C. trachomatis infectivity 
 
Similarly to supernatants, Lactobacillus-cell pellets (CP) were tested at three different 
concentrations (2.5×108, 2.5×107, and 2.5×106 CFU/mL) and time points (7, 15, 60 min) 
(Figure 12). 
At the concentration of 2.5×108 CFU/mL, five Lactobacillus strains: L. crispatus (BC1, 
BC3-BC5) and L. gasseri BC13 strongly reduced C. trachomatis infectivity at any time 
point. At short contact times (7 and/or 15 min) a significant inhibitory activity was 
observed for ten lactobacilli: L. crispatus (BC6-BC8), L. gasseri (BC9-BC12), and L. 
vaginalis (BC15-BC17). Lactobacillus crispatus BC2 and L. gasseri BC14 cells did not 
affect C. trachomatis EBs infectivity (Figure 12A). At the intermediate concentration of 
Lactobacillus-CP (2.5×107 CFU/mL), only L. crispatus BC3 retained a strong inhibitory 
activity at any time point. Lactobacillus crispatus (BC1, BC2, BC4, BC6, BC8), L. gasseri 
(BC9, BC11, BC13), and L. vaginalis BC15 significantly reduced C. trachomatis 
infectivity at short exposure times, while L. crispatus BC7 showed activity after 60 minutes 
of contact. No inhibitory effect was exerted by L. crispatus BC5, L. gasseri (BC10, BC12, 
BC14), and L. vaginalis (BC16, BC17) (Figure 12B). At the concentration of 2.5×106 
CFU/mL, L. crispatus BC3 cells were still able to inhibit C. trachomatis infectivity at all 
contact times, and L. crispatus (BC1, BC2, BC4-BC8) and L. gasseri (BC9, BC13) were 
effective at short time points. Cells from L. gasseri (BC10-BC12, BC14) and L. vaginalis 
(BC15-BC17) did not show any inhibitory effect (Figure 12C). 
 
In analogy with the results obtained using the lactobacilli supernatants, L. crispatus cells 
were the most effective in reducing C. trachomatis infectivity, exhibiting good inhibitory 
skills at the concentration of 2.5×108 CFU/mL, and being almost all active after dilution 
for at least one time point. L. gasseri and L. vaginalis cell pellets showed a more 
concentration-dependent activity, since their dilution caused the loss of Chlamydia 
inhibition for four L. gasseri strains (out of six) and for all L. vaginalis strains. Moreover, 
the challenge experiments with lactobacilli cells confirmed the major efficacy for short 
contact times (7 and/or 15 min), independently of the cell concentration. 
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Figure 12. Effect of Lactobacillus-CP on C. trachomatis infectivity. Experiments were 
performed at different concentrations of cell pellets: 2.5×108 CFU/mL (A), 2.5×107 
CFU/mL (B), and 2.5×106 CFU/mL (C), and different time points: 7 minutes (white 
bars), 15 minutes (grey bars) and 60 minutes (black bars). Chlamydia infectivity was 
evaluated as number of IFU/microscopic field. The results were expressed in percentage 
compared with control, taken as 100% (dotted bars). Bars represent median values, error 
bars represent median absolute deviations. Statistical significance was calculated vs 
control. * p < 0.05 
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4.2.3 C. trachomatis inhibition by lactic acid and hydrochloric acid 
 
The effect of lactic acid on C. trachomatis infectivity was evaluated after challenge of 
Chlamydia EBs for 7, 15, and 60 min. Two concentrations of lactic acid (10 mM, 50 mM), 
corresponding to the mean and higher titer registered by 1H-NMR in Lactobacillus-CM 
(Table 3), were tested. Lactic acid solutions were buffered at two pH values (pH 4, pH 7), 
corresponding to the pH range measured in Lactobacillus-CM. The effect of HCl on C. 
trachomatis infectivity was evaluated in the same experimental conditions to compare the 
effects of lactic acid with an inorganic acid (Figure 13). 
At pH 4, lactic acid was able to strongly inhibit EBs infectivity, both at 10 and 50 mM, and 
for all exposure times. In contrast, lactic acid lost its chlamydiacidal activity when buffered 
at pH 7, independently of contact time (Figure 13A). HCl did not interfere with Chlamydia 
infectivity, both at 10 mM or 50 mM, and at any pH value (Figure 13B). These results 
indicate that the presence of a high concentration of H+ ions is essential but not sufficient 
for the inhibition of Chlamydia EBs. 
 
  
Figure 13. Effect of Lactic/HCl acid on Chlamydia infectivity. Chlamydia infectivity was 
evaluated after challenging with lactic (A) or HCl (B) acid at different concentrations (10 
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mM, 50 mM), pH values (4, 7), and time points: 7 min (white bars), 15 min (grey bars), 
and 60 min (black bars). Infectivity was evaluated as number of Chlamydia 
IFU/microscopic field. The results were expressed in percentage compared with control 
(100%, dotted bars). Bars represent median values, error bars represent median absolute 
deviations. Statistical significance was calculated vs control. * p < 0.05. 
 
4.2.4 Ranking of lactobacilli in relation to anti-Chlamydia activity 
 
With the aim to delineate a ranking of Lactobacillus strains on the basis of their capability 
to counteract Chlamydia infectivity, we approached a statistical analysis on the entire set 
of median values, considering any concentration and time point. As a first step, we 
wondered if Lactobacillus-CP and CM fractions were equally effective in reducing 
Chlamydia infectivity. We firstly compared all median data collected from Chlamydia EBs 
pre-incubated with CP fractions with the data of untreated EBs, by means of a non-
parametric statistical test: the infectivity of Chlamydia EBs pre-incubated with 
Lactobacillus-CP was not significantly different from the infectivity of untreated EBs (p = 
0.4245, 1-tailed Wilcoxon signed rank test). Similarly, we compared median data obtained 
with Chlamydia EBs pre-incubated with Lactobacillus-CM fractions to data of untreated 
EBs, and we ascertained that pre-incubation of EBs with CM significantly reduced 
Chlamydia infectivity (p = 0.0384). Indeed, comparing data obtained with CP-treated EBs 
to those obtained with CM-treated EBs we confirmed that anti-Chlamydia effect of 
Lactobacillus-CM were significantly different from that of the respective CP (p = 0.0043). 
Being Lactobacillus-CM the fraction capable of reducing Chlamydia infectivity, we 
classified lactobacilli only on the basis of the anti-Chlamydia activity. For each 
Lactobacillus strain, CM efficacy has been expressed as the odds between data collected 
with CM-treated EBs and untreated EBs (control, taken as 100%), by means of the 1-tailed 
Wilcoxon signed rank p-values. A low p-value indicates that medians obtained with 
Chlamydia EBs pre-incubated with Lactobacillus-CM are different from the control. 
Conversely, a high p-value denotes that medians obtained with Chlamydia EBs pre-treated 
with Lactobacillus-CM are similar to the control. Thus, we classified Lactobacillus strains 
into 3 groups in relation to the inhibitory activity (Figure 14). The first group (H, high 
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activity) consists of lactobacilli with p-values below 0.2; the second group (I, intermediate 
activity) consists of lactobacilli with p-values ranging between 0.2 and 0.6; the last group 
(L, low activity) comprises lactobacilli with p-values over 0.6. Group H counts 7 strains 
(BC1, BC2, BC4, BC6, BC7, BC8, BC13), group I comprises 5 strains (BC5, BC9, BC11, 
BC15, BC16), group L included 5 strains (BC3, BC10, BC12, BC14, BC17). 
 
 
Figure 14. Ranking of lactobacilli in relation to anti-Chlamydia activity. Lactobacillus 
strains were classified on the basis of the inhibitory activity of their conditioned medium 
(CM), expressed as the difference between CM-treated EBs and untreated EBs, by means 
of the 1-tailed Wilcoxon signed rank P-values. Group H comprises lactobacilli strains with 
p-values below 0.2, group I comprises of lactobacilli with p-values ranging between 0.2 
and 0.6; group L comprises lactobacilli with p-values over 0.6. 
 
4.2.5 Identification of Lactobacillus metabolic profiles associated with anti-Chlamydia 
activity 
 
All Lactobacillus-CM were analyzed by 1H-NMR. We identified 40 metabolites mainly 
belonging to the families of aminoacids, organic acids monosaccharides, ketones, and 
alcohols (Table 3). A Principal Component Analysis (PCA) model was built on the 
concentrations of the identified molecules in order to search for correlations between anti-
Chlamydia activity and metabolome of lactobacilli (Figure 15). In the biplot describing the 
distribution of Lactobacillus strains in relation to the pool of metabolites, Principal 
Component (PC) 1 and PC2 accounted for the 44.3% of the whole variance of the 
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investigated samples (Figure 15A). The first component PC1, accounting for the 25.8% of 
the total variance, was mainly influenced by the taxonomy of lactobacilli. The second 
component PC2, accounting for the 18.5% of the total variance, was mainly influenced by 
the activity of lactobacilli against Chlamydia. The correlation between metabolome and 
anti-Chlamydia activity was best visualized by means of box plots representing the 
distribution of the groups of lactobacilli (H, I, L) (Figure 15B). Strains with different anti-
Chlamydia activity were clearly separated in the vertical direction: the most active strains 
occupied the lower positions while the less active strains were placed in the higher areas 
of the two-dimensional space. The highest metabolic homology was observed within the 
group of lactobacilli exerting high activity, as demonstrated by the lower height of the 
corresponding boxplot. 
 
  
Figure 15. Correlation between Lactobacillus metabolome and inhibitory activity 
towards C. trachomatis. (A) Score plot of Lactobacillus strains on PC1 and PC2 of a PCA 
model built on the total metabolites identified by 1H-NMR in Lactobacillus-CM. High 
activity (H), intermediate activity (I), and low activity (L) indicate the median values of 
lactobacilli grouped according to anti-Chlamydia activity. Strains without marks belong 
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to group H; underlined strains belong to group I; strains within rectangles belong to group 
L. Expl. Var, explained variance. (B) Box plots representing the distribution of activity 
against Chlamydia in relation to the metabolome. Lines within the boxes indicate the 
median values of the samples groups corresponding to the different activity scores. Each 
box represents the interquartile range (25–75th percentile). The bottom and top bars 
indicate the 10th and 90th percentiles, respectively. 
 
We searched which metabolites varied in relation to anti-Chlamydia activity, according to 
the approach of De Filippis et al. [De Filippis et al., 2014]. Orotate was produced in greater 
concentrations by lactobacilli highly active (group H) while phenylalanine, isoleucine, 
valine, and tyrosine were produced in greater concentrations by lactobacilli less effective 
against Chlamydia (group L). Orotate and phenylalanine production was found to be 
statistically different between lactobacilli in groups H and L (Orotate, p = 0.005; 
Phenylalanine, p = 0.005; 2-tailed Wilcoxon signed rank test). Inhibitory activity of orotate, 
at the highest concentration found in Lactobacillus-CM (30 mM), was tested, but no 
significant reduction of C. trachomatis infectivity was observed. Orotic acid was also 
tested in association with lactic acid (10/50 mM; pH: 4/7), but this combination did not 
enhance the lactic acid effect. 
Moreover, we observed that glucose was consumed at higher levels by lactobacilli 
belonging to group H while tryptophan was consumed more by lactobacilli of group L. 
Thus, to understand whether the competition for the carbonate source could be an 
additional mechanism of action towards Chlamydia, we added glucose (30 mM) to the 
supernatants of L. crispatus BC1 and L. gasseri BC13 (they consumed the highest amount 
of glucose within the H group). The addition of glucose to L. crispatus BC1 supernatant 
led to a significant increase (51 fold) of C. trachomatis infectivity at the shortest contact 
time (7 min), while no increase of infectivity was found at the time points 15 and 60 min. 
Similarly, L. gasseri BC13 supernatant enriched with glucose showed a reduction in anti-
Chlamydia activity both after 7 minutes (infectivity increase: 8.7 fold) and 15 minutes 
(infectivity increase: 6.1 fold) of contact (Table 5). These data confirm the importance of 
the depletion of glucose as an additional mechanism for the inhibition of C. trachomatis 
EBs by vaginal lactobacilli, in particular for short contact times. 
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Strain 
Contact time 
7 min 15 min 60 min 
L. crispatus BC1 51.2* - - 
L. gasseri BC13 8.7* 6.1* - 
 
Table 5. Increase of C. trachomatis infectivity following the addition of glucose to 
supernatants of L. crispatus BC1 and L. gasseri BC13. Dilutions 1:1 of Lactobacillus-
CM were tested. Increase was calculated as ratio between the infectivity of the supernatant 
added with glucose 30 mM and the infectivity of the corresponding not enriched 
supernatant. Significant increases were indicated with an asterisk (p < 0.05, 1-tailed 
Wilcoxon matched paired rank test). (-) No variation. 
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4.3 Role of vaginal lactobacilli against HIV-1 replication in human tissues ex vivo 
 
4.3.1 Lactobacillus colonization of tissue explants 
 
Fifteen Lactobacillus strains belonging to L. vaginalis, L. gasseri, and L. crispatus were 
evaluated for their capacity to colonize ex vivo tissue blocks. All lactobacilli colonized 
tissue explants with similar kinetics, reaching maximum colonization (approximately 1× 
108.5 CFU/mL) after three days of culture, and then plateaued for the entire 12 days of 
culture duration (Figure 16A). Cell depletion in tissue explants by lactobacilli was 
evaluated 3 days after bacterial inoculation (Figure 16B). Colonization of explants with six 
out of fifteen Lactobacillus strains, L. crispatus (BC3, BC5), L. gasseri (BC12, BC13), and 
L. vaginalis (BC16, BC17), did not result in cell depletion, as compared with control 
(Figure 16B lower panel, BC5 representative of this group). In contrast, the colonization 
of tissue blocks by the remaining nine Lactobacillus strains, L. crispatus (BC1, BC4, BC6, 
BC7, BC8) and L. gasseri (BC9, BC10, BC11, BC14), resulted in a loss of T cells (CD3+) 
as well as an increase in the expression of the apoptotic marker Bcl 2 (data not shown). 
The losses of CD3+ cells were not characteristics of particular species of Lactobacillus, as 
some strains of L. crispatus, L. gasseri, and L. vaginalis induced cell depletion while others 
did not. Lactobacillus strains that induced CD3+ cell depletion were not used in further 
experiments. 
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Figure 16. Lactobacillus colonization of ex vivo tissue. (A) Tonsillar tissues were 
colonized with fifteen vaginal Lactobacillus strains: L. crispatus (BC1, BC3–BC8), L. 
gasseri (BC9-BC14), and L. vaginalis (BC16, BC17), at a starting inoculum of 1 ×104 
CFU/mL and cultured for 12 days. Lactobacillus colonization was evaluated every 3 days 
spectrofometrically by measuring OD600. Bars represent mean ± SD from tissues of three 
donors. (B) We evaluated tissue cell depletion induced by Lactobacillus colonization of ex 
vivo tissues 3 days after bacterial inoculation using flow cytometry. Panels (from left to 
right) represent live/dead staining, CD3+ expression in live cells, and Bcl-2 expression in 
CD3+ cells in control (upper row) and L. crispatus BC5–colonized tissue (lower row). 
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4.3.2 Lactobacillus-CM inhibits HIV-1 replication 
 
To investigate the effects of metabolites secreted by lactobacilli on HIV-1 replication in ex 
vivo tissues, tissue blocks were pre-incubated with Lactobacillus-CM of L. crispatus (BC3, 
BC5), L. gasseri (BC12, BC13), and L. vaginalis (BC16, BC17), infected with HIV-1, and 
cultured as described in Materials and Methods. In both cervico-vaginal and lymphoid 
tissue blocks all undiluted Lactobacillus-CM suppressed replication of HIV-1 compared 
with the control by 91.9±4.3% and 98.3±1.4%  (L. crispatus BC3, p < 0.0001, n = 5), 
95.9±4.8% and 97.7±1.8% (L. crispatus BC5, p < 0.0001, n = 5), 93.5±3.6% and 
98.2±1.9% (L. gasseri BC12, p < 0.0001, n = 5), 91.9±1.5% and 98.3±2.3% (L. gasseri 
BC13, p < 0.0001, n = 5), 95.9±5.0% and 98.1±2.9% (L. vaginalis BC16, p < 0.0001, n = 
5), 85.8±11.7% and 95.0±6.5% (L. vaginalis BC17, p < 0.0001, n = 5), respectively (Figure 
17). All Lactobacillus-CM had an inhibitory effect on HIV-1 replication even when diluted 
5-fold. Depending on the Lactobacillus strain, inhibition of HIV-1 replication by such 
diluted medium was ranging from 44.3±31.7% (L. crispatus BC3, p = 0.0038, n = 5) to 
77.3±7.3% (L. vaginalis BC16, p < 0.0001, n = 5) in cervico-vaginal tissue (Figure 17B) 
and from 55.5±13.2% (L. vaginalis BC17, p < 0.0001, n = 5) to 93.1±5.2% (L. crispatus 
BC5, p = 0.0001, n = 5) in tonsillar tissue (Figure 17D). 
 
Chapter 4: Results 
	 68	
 
Figure 17. HIV-1 infection of human tissue ex vivo treated with Lactobacillus-CM. 
Cervico-vaginal (A, B) and tonsillar (C, D) tissue blocks were pre-incubated with 
undiluted or diluted 1:5 Lactobacillus-CM from six strains: L. crispatus (BC3, BC5), L. 
gasseri (BC12, BC13), and L. vaginalis (BC16, BC17). Tissue cultures were infected with 
HIV-1 and kept in the Lactobacillus-CM for 3 days. At day 3, the Lactobacillus-CM was 
removed and cultures were kept in regular medium until day 12 post-infection. (A, C) 
Kinetics of HIV-1 replication in tissues was obtained by measuring the levels of p24gag in 
tissue culture medium. (B, D) Replication of HIV-1 in Lactobacillus-treated tissues 
expressed as percentages of HIV-1 replication compared to the control (black bars). Bars 
represent mean±SD from five tissue donors. Asterisks indicate statistical significance vs. 
control, obtained by one-way ANOVA multiple comparisons (*p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001). 3TC (lamivudine, 10 µM), a powerful HIV-1 inhibitor, used as 
a positive control. 
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4.3.3 Effects of lactic acid and pH on HIV-1 replication 
 
To investigate whether lactic acid produced by lactobacilli is responsible for HIV-1 
inhibition, we measured the concentrations of lactic acid isomers D and L in Lactobacillus-
CM (Table 6). 
 
Lactobacillus 
strains 
[D-Lactate] [L-Lactate] pH 
mM 
 
mM/ 
108 
bacteria 
mM 
 
mM/  
108 
bacteria 
Lactobacillus-CM 
 
Lactobacillus-
CM  
1:5 
L. crispatus BC3 3.1 0.4 15.1 2.2 4.0 6.6 
L. crispatus BC5 3.1 0.3 24.0 2.4 3.8 6.4 
L. gasseri BC12 3.6 0.4 24.7 2.8 3.8 6.3 
L. gasseri BC13 3.2 0.3 22.2 2.0 3.8 6.4 
L. vaginalis BC16 2.7 0.3 22.4 2.2 3.8 6.4 
L. vaginalis BC17 1.8 0.4 9.0 1.9 4.6 6.9 
 
Table 6. Lactic acid isomers D and L and pH in Lactobacillus-CM. Titers of lactate 
isomers D and L from overnight-cultured Lactobacillus-CM using a lactate quantification 
assay kit. pH values in all Lactobacillus-CM, undiluted or diluted 1:5, were measured as 
well. 
 
Depending on the strain, the concentrations of lactic acid isomers D and L ranged from 1.8 
to 3.6 mM and from 9.0 to 24.7 mM, respectively. L. gasseri BC12 was the strain that 
produced the highest concentrations of both isomers, while L. crispatus BC17 was the 
strain that produced the lowest concentrations. Next, we tested the effects of lactic acid 
isomers at the concentration found in undiluted Lactobacillus-CM or CM diluted 1:5 on 
HIV-1 replication in tissues ex vivo (Figure 18). As shown in Figures 18A and C, lactic 
acid isomers D (3 mM), L (23 mM), and D + L (3; 23 mM) significantly reduced HIV-1 
replication in both cervico-vaginal and tonsillar tissues. We found that D lactate (3 mM) 
inhibited HIV-1 replication by 48.2±6.2% in cervico-vaginal (p = 0.0004, n = 3) and by 
57.6±33.2% in tonsillar (p = 0.0125, n = 3) tissue cultures, while L lactacte (23 mM) 
suppressed HIV-1 replication by 94.3±5.5% (p < 0.0001, n = 3) and by 99.3±21.9% (p < 
0.0001, n = 3) in cervico-vaginal and tonsillar tissues, respectively. The mixture of D + L 
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lactate suppressed HIV-1 replication by 92.1±7.7% in cervico-vaginal and by 94.4±30.4% 
in tonsillar tissue (p < 0.0001, n = 3) (Figures 18B and D). Afterward, we evaluated the 
effect of lactic acid isomers at the concentrations found in 5-fold-diluted Lactobacillus-
CM on HIV-1 replication in lymphoid tissue (Figures 18C and D). We found that isomer 
D did not inhibit HIV-1 replication while isomer L and the mixture of isomers D + L 
significantly reduced HIV-1 replication in tonsillar tissues by 67.8±0.8% (isomer L, p = 
0.0033, n = 3) and by 56.5±9.5% (isomers D + L, p = 0.0142, n = 3) (Figure 18D). 
 
Furthermore, we evaluated whether the effect of lactobacilli on HIV-1 replication is due to 
the acidic pH of the Lactobacillus-CM. As shown in Table 5, pH values of undiluted 
Lactobacillus-CM ranged from 3.8 to 4.6 and of 5-fold-diluted Lactobacillus-CM from 6.3 
to 6.9. To mimic the effect of pH on HIV-1 replication, we acidified the culture medium 
of human cervico-vaginal and tonsillar tissues with HCl. In the culture medium buffered 
to pH 4, HIV-1 replication was reduced in both cervico-vaginal (90.1±0.1%, p < 0.0001, n 
= 3) and tonsillar tissue (88.0±17.5%, p = 0.0003, n = 3) compared with control tissue 
blocks cultured in regular medium (Figures 18B and D). No statistically significant 
inhibition of HIV-1 replication in cervico-vaginal or tonsillar tissues was observed when 
the culture medium was buffered to pH 6.9 (21.6±18.8%, p = 0.1492, n = 2 and 
14.28±10.19%, p = 0.9, n = 3, respectively). 
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Figure 18. Effect of lactic acid isomers and of pH on HIV-1 replication. The effects of 
lactate isomers D and L on HIV-1 replication were tested in cervico-vaginal (A, B) and 
tonsillar (C, D) tissues. Isomers D (3 mM), L (23 mM), and D + L (3 mM + 23 mM), 
corresponding to the average titers found in all undiluted Lactobacillus-CM were tested. 
We evaluated the effect of acidic pH on HIV-1 infectivity in ex vivo tissues by buffering the 
culture medium at pH 4 and pH 6.9 using HCl. (A, C) We evaluated the kinetics of HIV-1 
replication in tissues by measuring the levels of p24gag in culture medium. (B, D) 
Replication of HIV-1 in Lactobacillus-treated tissues was expressed as percentage of HIV-
1 replication in untreated control (black bars). Statistical significance vs. control is 
presented. Bars represent mean ± SD from tissues of three to five donors. Asterisks indicate 
statistical significance by one-way ANOVA multiple comparison (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001). 
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4.3.4 Virucidal capacity of Lactobacillus-CM against HIV-1 
 
In order to understand whether Lactobacillus-CM can suppress HIV-1 infectivity before 
interaction with tissues, we pre-incubated HIV-1 for 1 h with Lactobacillus-CM (diluted 
1:5) and tested HIV-1 infectivity in cervico-vaginal tissues ex vivo. We studied the 
virucidal capacities of Lactobacillus-CM of six strains: L. crispatus (BC3, BC5), L. gasseri 
(BC12, BC13), and L. vaginalis (BC16, BC17). As shown in Figure 19A, HIV-1 replication 
was reduced when cervico-vaginal tissues were infected with HIV-1 pre-treated with 
Lactobacillus-CM from L. crispatus BC3 (47.7±7.0%, p = 0.005, n = 5), L. crispatus BC5 
(60.9±13.8%, p = 0.0005, n = 5), L. gasseri BC12 (64.0±11.4%, p < 0.0001, n = 5), and L. 
vaginalis BC16 (57.4±8.1%, p = 0.003, n = 5) (Figure 19B). No statistically significant 
inhibition was observed due to Lactobacillus-CM from L. gasseri BC13 (28.6±6.6%, p = 
0.13, n = 5) and L. vaginalis BC17 (31.1±24.8%, p = 0.06, n = 5). 
 
 
Figure 19. Virucidal effect of Lactobacillus-CM against HIV-1. Virucidal capacities of 
six strains: L. crispatus (BC3, BC5), L. gasseri (BC12, BC13), and L. vaginalis (BC16, 
BC17) are presented. HIV-1 preparation was pretreated with Lactobacillus-CM diluted 
1:5 for 1 h, and HIV-1 infectivity was tested in cervico-vaginal tissues ex vivo. (A) Kinetics 
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of HIV-1 replication by measuring the levels of p24gag in tissue culture medium. (B) 
Replication of HIV-1 in Lactobacillus-treated tissues expressed as percentages of HIV-1 
replication in untreated control (black bars). Bars represent mean ± SD from tissues of 
five patients. Asterisks indicate statistical significance by one-way ANOVA multiple 
comparison (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 3TC used as a positive 
control. 
 
4.3.5 Virucidal capacity of Lactobacillus cells against HIV-1 
 
Similar to Lactobacillus-CM, the virucidal capacities of Lactobacillus-CP were studied. 
HIV-1 was first incubated with Lactobacillus-CP, and after bacteria have been washed off, 
the infectivity of HIV-1 was tested in cervico-vaginal tissues ex vivo. As shown in Figure 
20A, tissue infection with HIV-1 pre-incubated with Lactobacillus-CP for 1 h resulted in 
inhibition of HIV-1 replication by 64.7±14.9% for L. crispatus BC5 (p < 0.0001, n = 5), 
by 39.3±18.4% for L. gasseri BC12 (p = 0.0124, n = 5), and by 59.8±13.2% for L. vaginalis 
BC17 (p = 0.0002, n = 5). No statistically significant inhibition was observed with L. 
crispatus BC3 (19.4±18.5%, p = 0.46, n = 5), L. gasseri BC13 (16.1±27.9%, p = 0.64, n = 
5), and L. vaginalis BC16 (9.0±15.6%, p = 0.96, n = 5) (Figure 20B). 
Thereafter, to investigate whether this suppression of HIV-1 replication of cervico-vaginal 
tissue by L. crispatus BC5, L. gasseri BC12, and L. vaginalis BC17 in the above-described 
experiments was due to viral binding to Lactobacillus cells, we measured the concentration 
of p24gag on Lactobacillus-CP after bacteria were separated by centrifugation. We found 
that these three strains adsorbed 36.2±21.5%, 29.6±25.6%, and 39.2±9.6% of HIV-1, 
respectively, as evaluated from measurements of p24gag (Figure 20C). In the CP of the 
remaining strains (L. crispatus BC3, L. gasseri BC13, and L. vaginalis BC16) the p24gag 
was less than 10% of the original HIV-1 preparation (data not shown). 
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Figure 20. Virucidal effect of Lactobacillus-CPs against HIV-1. Virucidal capacity of six 
strains, L. crispatus (BC3, BC5), L. gasseri (BC12, BC13), and L. vaginalis (BC16, BC17) 
is presented. HIV-1 was pre-treated with Lactobacillus-CP at 1 ×108 CFU/mL, and HIV-
1 infectivity was then tested in cervico-vaginal tissues ex vivo. (A) We evaluated HIV-1 
replication kinetics in tissues by measuring p24gag in culture medium. (B) Replication of 
HIV-1 in Lactobacillus-treated tissues was expressed as percentage of HIV-1 replication 
in untreated control (black bars). (C) Fractions of p24gag associated with CP after 
incubation with HIV-1 are presented. Statistical significance vs. control was calculated. 
Bars represent mean ± SD from five patients. Asterisks indicate statistical significance by 
one-way ANOVA multiple comparison (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001). 3TC (lamivudine) at 10 µM we used in our study as a positive control. 
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5. DISCUSSION AND CONCLUSIONS 
 
The vaginal mucosa is normally colonized by a vast number of microorganisms 
collectively referred to as the vaginal microbiota, which normally coexist with the host in 
a tightly regulated manner [Petrova et al., 2015]. Healthy women of reproductive age are 
generally dominated by Lactobacillus species [Hyman et al., 2005; Pavlova et al., 2002; 
Ravel et al., 2011]. A Lactobacillus-dominated microbiota appears to be a biomarker for a 
healthy vaginal communities, as changes in the vaginal microbiota, especially shifting 
away from Lactobacillus dominance, are associated with bacterial vaginosis [Allsworth 
and Peipert, 2011; Cherpes et al., 2003], vulvo-vaginal candidiasis (VVC) [Goffeng et al., 
1997; Vitali et al., 2007], and increased risks of acquisition of sexually transmitted 
infections, including Chlamydia trachomatis [Brotman et al., 2010; Martius et al., 1988; 
Wiesenfeld et al., 2003] and human immunodeficiency virus (HIV) [Atashili et al., 2008; 
Gosmann et al., 2017; Mirmonsef and Spear; Nardis et al., 2013; Petrova et al., 2015; Taha 
et al., 1998]. 
 
The aim of the present study was to isolate vaginal lactobacilli from healthy women, to 
characterize them at a molecular level and to evaluate their antagonistic effect toward 
Candida spp., C. trachomatis, and HIV, which are among the infectious agents that most 
significantly affect women’s health worldwide. 
 
In this context, from vaginal swabs of healthy premenopausal woman we isolated 
seventeen Lactobacillus strains belonging to the 3 species highly represented in the human 
vaginal microbiota: L. crispatus (BC1-BC8), L. gasseri (BC9-BC14), and L. vaginalis 
(BC15 -BC17) [Parolin et al., 2015]. The isolation of L. crispatus has been strongly 
associated with a normal vaginal microbiota and absence of vaginal dysbiosis [Antonio et 
al., 1999]. Longitudinal studies have also shown that L. crispatus promotes stability of the 
vaginal microbiota [Petrova et al., 2015; Verstraelen et al., 2009], and seems to have a role 
in the restoration of the vaginal communities, and in the maintenance of remission from 
bacterial vaginosis, following antibiotic treatment [Cruciani et al., 2015]. Despite the high 
incidence of L. iners in the human vaginal microbiota, as detected by culture-independent 
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molecular studies [Ravel et al., 2011; van de Wijgert et al., 2014], we did not obtain isolates 
belonging to this species probably due to its stringent nutritional requirements and very 
low oxygen tolerance [Falsen et al., 1999]. On the other hand, as our goal was to identify 
health-promoting lactobacilli, L. iners was of little interest given its close correlation with 
vaginal dysbiosis [Macklaim et al., 2013]. 
In view of potential application of the isolated Lactobacillus strains as vaginal probiotics, 
we sought to characterize their capacities to produce antimicrobial compounds to 
individuate a possible antimicrobial mechanism of action. H2O2 and lactate are classically 
associated with the antimicrobial properties of Lactobacillus genus [Aroutcheva et al., 
2001]. All strains produced H2O2 in agreement with the assumption that the vaginal 
microbiota of healthy women is dominated by H2O2-producing lactobacilli [Pendharkar et 
al., 2013]. Also, lactate was produced by all lactobacilli, while butyrate was produced only 
by certain strains. 
 
The fungistatic and fungicidal activities of the vaginal lactobacilli were evaluated against 
of C. albicans and C. non-albicans strains, in the perspective to develop successful vaginal 
probiotics for VVC management [De Seta et al., 2014], considering that the high incidence 
and associated healthcare costs of VVC together with the growing problem of antibiotic 
resistance highlight the necessity for the development of new effective agents for the 
prevention and therapy of this gynaecological infection [Coste et al., 2007; Falagas et al., 
2006]. Compared to previous studies focused on the antifungal activity of lactobacilli 
[Abramov et al., 2014; Kohler et al., 2012], our work has the additional value examining 
Lactobacillus isolates from vaginal source against numerous clinical isolates of Candida 
species. Therefore, the results obtained in this work provide important information about 
the real applicability of vaginal lactobacilli in the prevention and treatment of VVC. The 
broadest spectrum of activity was observed for L. crispatus (BC1, BC4, BC5) and L. 
vaginalis BC15, exhibiting fungicidal activity against all isolates of C. albicans and C. 
lusitaniae. Among these strains, L. crispatus BC1 and L. vaginalis BC15 exhibited the best 
anti-Candida profile covering also C. tropicalis and C. glabrata. 
Next, we evaluated the interference of lactobacilli with pathogens adherence to human 
cells, considering this aspect of a major importance for the in vitro evaluation of probiotic 
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properties [FAO/WHO, 2006]. We observed that most of Lactobacillus strains 
significantly reduced C. albicans adhesion to HeLa cells through multiple mechanism 
including exclusion, competition, and displacement. Lactobacillus crispatus BC2 and L. 
gasseri (BC10, BC11) appeared to be the most active strains in reducing pathogen 
adhesion, as their effects were mediated by both Lactobacillus-cell pellet (CP) and 
Lactobacillus-conditioned medium (CM). Interestingly, the same bacteria were not the 
most adhesive strains suggesting that the inhibitory effects are not merely due to steric 
encumbrance and/or saturation of the adhesion sites, but rather to a reduction of the 
adherence of the pathogen itself and/or to modifications of the epithelial cells surface. 
Additionally, the same lactobacilli were not the best performing strains in terms of 
fungistatic/fungicidal activity. These findings suggest that lactobacilli isolated from 
healthy vagina can exert their protective role against Candida infection utilizing one 
strategy (either inhibition of growth or adhesion) rather than through the combination of 
two complementary mechanisms. 
To interpret the differences in fungistatic/fungicidal capacities of the vaginal lactobacilli, 
through a metabolic key, we studied by 1H-NMR the metabolome of Lactobacillus-CM 
and we looked for correlations with taxonomy and activity score. The strong correlation 
between metabolic profile and taxonomy highlighted the inter-specific variability of 
bacterial metabolism. Metabolic variance was also related to antifungal activity, 
confirming the excellent antifungal profile of most L. crispatus strains and L. vaginalis 
BC15. These data highlight the potential of metabolomics to measure the taxonomic 
distance between different Lactobacillus strains and predict their anti-Candida activity. 
Although metabolomics has been applied to evaluate the impact of probiotics on the host 
organism [Bisanz et al., 2014], to our knowledge this is the first study employing a 
metabolomic approach to investigate the antimicrobial activity of health-promoting 
bacteria, representing a new idea for future researches. 
Since butyrate is a known histone deacetylase (HDAC) inhibitor [Nguyen et al., 2011], we 
hypothesize that it may enhance the anti-Candida activity of lactobacilli through histone 
hyper-acetylation. Inhibition of HDACs can influence fungal growth and adherence to host 
cells [Nguyen et al., 2011; Simonetti et al., 2007]. We observed that histone hyper-
acetylation was a predominant capacity of most vaginal lactobacilli. Interestingly, the 
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strains that did not trigger histone acetylation (L. gasseri BC13 and L. vaginalis BC17) 
were the same ones that did not exercise any fungicidal activity or interference on Candida 
adhesion, suggesting that inhibition of HDACs could support antifungal activity of vaginal 
lactobacilli. 
 
This study also provides experimental evidence for inhibition of C. trachomatis infection 
by vaginal lactobacilli. Chlamydia trachomatis is the most common cause of bacterial 
sexually transmitted infections in the world [Miller et al., 2004; Senior, 2012]. It has been 
hypothesized that Lactobacillus species play a critical protective role in the vaginal habitat 
by producing lactic acid, which maintain an acidic environment inhibiting sexually 
transmitted pathogens. Gong et al. suggested that acidic pH is fully responsible for 
chlamydiacidal activity of lactobacilli [Gong et al., 2014]. 
Our study showed that Lactobacillus strains exert a strong inhibitory effect on Chlamydia 
infectivity mainly through metabolites secreted out of the cell, in a concentration-
dependent manner. We observed that the factor “concentration” is inversely correlated to 
the pH of the culture medium. Indeed, all Lactobacillus-CM were characterized by low pH, 
while diluted Lactobacillus-CM showed higher pH. 
The factor “contact time” also seems to play a role in the inhibitory activity against 
Chlamydia. Lactobacilli, especially Lactobacillus cells, were more effective in inhibiting 
Chlamydia EBs infectivity at short contact times. This inhibition may be generated by a 
rapid and dynamic modification of Chlamydia EBs membrane; we assume that this 
modification could revert for longer exposure times. These findings suggest that 
lactobacilli could exert their protective role against Chlamydia in the early steps of the 
infection, probably due to inactivation of EBs before they can colonize and infect the 
epithelial host cells; these results are in accord to results previously described 
[Mastromarino et al., 2014]. 
Using a statistical approach, we classify Lactobacillus strains according to their anti-
Chlamydia activity into three groups: high, intermediate, and low activity. The best anti-
Chlamydia profile was shown by strains belonging to L. crispatus species. Conversely, L. 
gasseri and L. vaginalis showed a heterogeneous spectrum of activity. It has been reported 
that L. crispatus inhibit in vitro the growth of uropathogens and block their adhesion to 
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vaginal epithelial cells [Osset et al., 2001]. Lactobacillus crispatus was also shown to 
reduce the adhesion of Neisseria gonorrhoeae [Vielfort et al., 2008] and C. trachomatis 
[Mastromarino et al., 2014] to HeLa cells by competitive exclusion. Moreover, it was 
demonstrated the efficacy of L. crispatus to limit the inflammatory reaction in C. 
trachomatis-infected HeLa cells and macrophages [Rizzo et al., 2015]. 
Directly linked to the presence of lactobacilli, the production of lactic acid is accepted as a 
hallmark beneficial activity of the vaginal microbiota. Lactic acid has been associated with 
pathogen exclusion and its concentration could also be an important biomarker of vaginal 
health, although the current evidence is still mainly based on in vitro studies. Lactic acid is 
able to inactivate a wide range of reproductive tract pathogens, including C. trachomatis 
[Gong et al., 2014] and HIV-1 [Aldunate et al., 2013]. We investigated whether the anti-
Chlamydia activity of lactic acid is merely associated with the pH, or other mechanisms 
may be involved. Lactic acid, at the concentrations found in the Lactobacillus-CM, 
strongly inhibit EBs infectivity only at acid pH for all exposure times, differently from HCl 
that did not show any activity in the same experimental conditions. These results indicate 
that a high concentration of H+ ions is necessary but not sufficient to inhibit Chlamydia 
EBs. Therefore, the presence of lactic acid in an acidic environment seems to be crucial for 
this activity. It remains to elucidate the specific mechanisms by which lactate moiety 
inactivates chlamydial EBs. Notably, the inhibitory activity exerted by most of 
Lactobacillus-CM, characterized by similar lactate concentrations and pH values, was 
higher than that exerted by lactic acid solution, suggesting that other metabolites present 
in lactobacilli supernatants could determine a synergistic effect. Because L. crispatus 
strains were found to be the most active in counteracting Chlamydia infection, we assume 
that the effect of lactic acid may be enhanced by the pool of metabolites especially 
produced by this species. 
Given the importance of the metabolic component in determining the inhibition of 
Chlamydia, we studied the metabolic profiles of lactobacilli supernatants by 1H-NMR to 
identify active metabolites and to find correlations between metabolism of lactobacilli and 
anti-Chlamydia effect. Metabolic variance was strictly correlated with the Chlamydia 
inhibitory activity, confirming the excellent anti-chlamydial profile of the majority of L. 
crispatus strains. Interestingly, the metabolomic analysis highlighted the increased 
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consumption of glucose by the strains highly active against Chlamydia. We demonstrated 
that glucose depletion represents an additional mechanism of action for lactobacilli 
antagonism toward Chlamydia. It has been recently reported that C. trachomatis EBs have 
considerable metabolic and biosynthetic activity and utilize glucose as an energy source 
[Omsland et al., 2012] to fuel the developmental transition of EB to RB [Saka et al., 2011]. 
Consumption of glucose and production of organic acids are metabolically interrelated and 
represent defensive strategies implemented by vaginal lactobacilli against the attack of 
pathogens, such as Chlamydia. Notably, an increase of glucose concentration in the vaginal 
fluids collected from women affected by bacterial vaginosis was reported [Vitali et al., 
2015]. These findings can be interpreted by assuming that the lack of lactobacilli, mainly 
those strains with high efficiencies of glucose fermentation, is associated with a greater 
availability of glucose in the vaginal environment. We hypothesize that the availability of 
glucose, in turn, could promote growth of undesirable microorganisms, including bacteria 
responsible for bacterial vaginosis and chlamydiae. 
 
We also studied the role of vaginal lactobacilli in HIV pathogeneses and transmission. The 
vaginal microbiota seems to protect against HIV directly, by production of antiviral 
compounds (lactic acid, hydrogen peroxide, bacteriocins, and lectin molecules), or 
indirectly, stimulating immune responses or inhibiting colonization of microorganisms that 
cause bacterial vaginosis [Petrova et al., 2015; Petrova et al., 2013]. 
Here, we investigated some of these mechanisms by studying the effects of vaginal 
lactobacilli on HIV-1 in the context of human cervico-vaginal and tonsillar tissues ex vivo 
[Introini et al., 2014; Merbah et al., 2011; Saba et al., 2010]. These human tissue cultures 
offer major advantages over single-cell cultures, as they retain general tissue 
cytoarchitecture and important functional aspects of cell–cell interactions [Grivel and 
Margolis]. Therefore, they remain a model of choice to study host–pathogen interactions 
(reviewed in Grivel and Margolis, 2009). These ex vivo tissues have proved to be useful in 
studies of the effect of HIV-1 copathogens on HIV-1 replication [Grivel et al., 2001; Lisco 
et al., 2007; Vanpouille et al., 2007] as well as in pre-clinical drug testing [Andrei et al., 
2011; Vanpouille et al., 2012]. 
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To address the effects of lactobacilli on HIV-1 infection in the context of human tissues, 
we first colonized them ex vivo with different strains of Lactobacillus. We found that all 
lactobacilli colonized and grew in human tissues ex vivo to densities comparable with those 
observed in vaginal specimens [Aleshkin et al., 2011; Antonio et al., 2009]. Tissue 
colonization with some of the tested bacterial strains resulted in the depletion of T cells. 
Although this phenomenon maybe relevant to the protection against HIV-1 in vivo, we 
focused our study on six strains of Lactobacillus (L. crispatus BC3, BC5; L. gasseri BC12, 
BC13; and L. vaginalis BC16, BC17) that did not deplete cells in tissue. We found that all 
these lactobacilli efficiently suppressed HIV-1 replication in human tissues ex vivo, and we 
investigated the mechanisms of this phenomenon. 
First, we investigated whether lactobacilli release suppressive factors that inhibit HIV-1 
replication in human tissues ex vivo. We found that they do indeed release factors that 
suppress HIV-1 replication, since the CM inhibited HIV-1 replication in human cervico-
vaginal and tonsillar tissues. 
Although such a medium may contain multiple inhibitory factors, we first focused on two 
of them, pH and lactic acid, whose roles in suppressing HIV infection were suggested 
earlier [Aldunate et al., 2013; Martin et al., 1985; O'Connor et al., 1995; Ongradi et al., 
1990]. Depending on the bacterial strain, the pH of Lactobacillus-CM varied from 3.8 to 
4.6. We adjusted the pH of the tissue culture to these pH values, and in agreement with 
earlier studies [Martin et al., 1985; Ongradi et al., 1990; Ravel et al., 2011] we found that 
this acidification may be directly responsible for HIV-1 inhibition. Low pH (<4.5) is typical 
for the vaginal communities in vivo that are dominated by Lactobacillus species in healthy 
women [Boskey et al., 1999; Fox et al., 1973; O'Hanlon et al., 2013]. However, during 
vaginal intercourse, vaginal fluid is diluted by HIV-containing semen, resulting in neutral 
pH [Tevi-Benissan et al., 1997]. Also, in the presence of vaginal dysbiosis (i.e., bacterial 
vaginosis), vaginal pH increases [Onderdonk et al., 2016]. Therefore, in our experiments 
we diluted CM with normal media, resulting in a pH between 6.3 and 6.9; this diluted CM 
was still inhibitory for HIV-1 replication in human tissue ex vivo. Control experiments with 
pH 6.9 demonstrated no HIV-1 suppression, suggesting that other factors beyond lowered 
pH may also be important for HIV-1 inhibition, at least for some of the lactobacilli. 
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One such factor considered in the literature is the major Lactobacillus metabolite lactic 
acid [O'Hanlon et al., 2011, 2013]. The importance of this metabolite is evidenced by the 
fact that in our experiments we observed a correlation between the capacity of supernatant 
of lactobacilli to inhibit HIV-1 replication and the capacity of lactobacilli to produce lactic 
acid. Therefore, we investigated the effect of lactic acid isomers D and L on HIV-1 
infection. We found that the addition of these isomers to tissue culture medium at 
concentrations that corresponded to their amounts released by lactobacilli resulted in HIV-
1 inhibition. In our work, the racemic lactic acid in Lactobacillus-CM ranged from 10.8 to 
28.3 mM and thus was not higher than the physiological level, reported to be around 110 
mM [O'Hanlon et al., 2013]. The protective effect of lactic acid in our ex vivo tissue system 
is in agreement with the work of Nunn et al., who reported that a high concentration of 
lactic acid in cervico-vaginal mucus plays an important role in protection against HIV-1 
and other sexually transmitted infections [Nunn et al., 2015]. We found that the L isomer 
rather than the D isomer was predominantly responsible for HIV-1 inhibition. These results 
indicated that lactic acid, in particular its L isomer, inhibited HIV-1 replication, 
independently from lowering the pH.  
Next, we investigated whether Lactobacillus could have a direct virucidal effect on HIV-
1. To answer this question, we incubated an HIV-1 preparation in Lactobacillus-CM and 
then tested HIV-1 infectivity in human tissue culture. We found that HIV-1 infectivity in 
cervico-vaginal tissue was significantly reduced. We previously reported similar findings 
when testing the effect of Lactobacillus-CM on C. trachomatis [Nardini et al., 2016]. 
Finally, we investigated whether direct interactions with lactobacilli themselves may affect 
HIV-1. We found that a significant fraction of virions are adsorbed on bacteria. These 
virucidal effects of lactobacilli may be relevant to the inhibition of HIV-1 transmission in 
vivo. 
In general, the level of HIV-1 suppression may depend on the superimposition of multiple 
mechanisms, different for each Lactobacillus strain. These mechanisms include change of 
pH, production of lactic acid, HIV adsorption on the surface of lactobacilli, etc. However, 
lactic acid produced by lactobacilli in the context of human tissues ex vivo seems to be a 
major cause of HIV-1 inhibition. 
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Several molecular mechanisms by which this metabolite may affect HIV-1 have been 
suggested. It was reported that lactic acid could disrupt cellular membranes [Alakomi et 
al., 2000], acidify cytosol [Russell and Diez-Gonzalez, 1998], unfold proteins [Tang et al., 
2003], and inhibit enzymatic activity [McWilliam Leitch and Stewart, 2002]. Any of these 
reported effects of lactic acid might be sufficient to suppress HIV infection, e.g., by 
destroying the viral envelope, unfolding gp120, and/or inhibiting HIV enzymes involved 
in the HIV cycle [Aldunate et al., 2013]. 
 
In conclusion, we identify vaginal lactobacilli active against Candida, C. trachomatis, and 
HIV-1 [Nahui Palomino et al., 2017; Nardini et al., 2016; Parolin et al., 2015]. We 
characterize the mechanisms of action underlying antagonism toward these pathogens. We 
have identified strains with a good spectrum of fungistatic/fungicidal activity (L. crispatus 
BC1 and L. vaginalis BC15) that may be associated with strains particularly active in 
reducing the adhesion of Candida (L. crispatus BC2, L. gasseri BC10, L. gasseri BC11). 
We demonstrate the ability of different Lactobacillus strains of vaginal origin to inactivate 
C. trachomatis through the production of extracellular metabolites in an acidic 
environment. We found that mostly species of L. crispatus inhibit C. trachomatis 
infectivity, stressing once again the importance of this species for the vaginal health. 
Finally, we found that lactobacilli inhibit HIV-1 replication in human tissue ex vivo by 
multiple mechanisms. 
 
Extrapolated to in vivo, our results may explain why the presence of normal vaginal 
microbiota, which include multiple species of Lactobacillus, is associated with a decreased 
risk of bacterial vaginosis, vulvo-vaginal candidiasis, and decreased risks of acquisition of 
sexually transmitted infections, including C. trachomatis and HIV. 
 
The positive effects of vaginal lactobacilli on the health of the female genital tract are 
generating increasing interest in the perspective of their use in probiotic formulations for 
the prophylaxis and therapy of several vaginal disturbances [Burton et al., 2003; Donders 
et al., 2010; Reid et al., 2001]. The application that follows is the combination of strains 
exerting different modes of action to obtain a probiotic blend with enhanced therapeutic 
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properties. The choice of different species is also an added advantage as it ensures a wider 
expression of metabolic functions. 
 
Further studies are necessary for a thorough understanding of the antagonistic mechanisms 
of vaginal lactobacilli against pathogens, i.e. study if lactobacilli release extracellular 
vesicles/exosomes (EVs) rather than just soluble bioactive molecules (organic acids, 
bacteriocins, H2O2, etc.). Nowadays, EVs are becoming more and more studied in various 
aspects of the biomedicine. EVs are produced by all domains of life. These EVs contain 
varied cargo, including nucleic acids, toxins, lipoproteins and enzymes, and have important 
roles in microbial physiology and pathogenesis. 
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